

Index

Page numbers in **bold** = tables, while those in *italics* = figures.

- abacavir, 272
- acicloguanosine: same as 'aciclovir' (*qv*), 263
- aciclovir, 57, 57, 140, 141, 142, 188, **204**, 268
- chickenpox, 231, 236
- chickenpox (during pregnancy), 185
- definition, 263
- encephalitis (as complication of chickenpox), 162
- HSV, 161, 163, 171, **204**, 213, 218, 231, 232
- inhibition of viral replication (two ways), 263
- keratitis, 204
- mechanism of action, 263–4
- meningitis, 163
- 'most successful antiviral agent', 263
- neonatal herpes infection, 188
- resistance, 264
- side effects 'limited', 263
- viral life-cycle target, **264**
- VZV, 163, 168, 213, 215, 218, 233, 290
- zoster treatment, 231
- acquired immunodeficiency syndrome (AIDS), 1, 61, 74, 220, 226, 264
- defining illnesses (groups), 62
- mortality, 59
- acute encephalitis, 122
- further reading, 164
- acute hepatitis, 31, 42, 51, 52
- laboratory diagnosis, 32
- acute hepatitis B virus, 35
- serological markers, 37
- acute kidney injury, 69
- acute parotitis, 94
- acute post-measles encephalitis, 90
- acute respiratory distress syndrome (ARDS), 179
- adaptive immune response, 3, 4–5
- antibody-mediated, 5
- cell-mediated, 4
- adefovir, 57, **269**
- viral life-cycle target, **264**
- adefovir dipivoxil, 40, 267
- Adenoviridae, 7
- adenovirus conjunctivitis (shipyard eye), 203
- adenovirus vector vaccines, 275–6, **276**
- adenoviruses, 7–10, 25, 98, 151, 165, 172, 173, 192, 196, 203, **204**, 266, **270**
- clinical, 8–9
- definition, 7
- epidemiology, 7–8
- immunocompromised patients, 218–19
- laboratory diagnosis, 173
- maculopapular skin rashes, **229**
- management, 9
- negatively stained (electron micrograph), 10
- respiratory virus symptoms in different groups of patients, **193**
- symptoms, 172
- transplant recipients, **214**
- viral rashes, 231
- adenoviruses (clinical), 8–9
- immunocompromised patients, 8
- laboratory diagnosis, 9, 9
- symptoms, 8
- adenoviruses (epidemiology), 7–8
- at-risk groups, 8
- incubation period, 7
- infectious period, 7
- prevalence, 7
- route of spread, 7
- adenoviruses (management), 9
- infection control, 10
- prophylaxis, 9
- treatment, 9
- adult T-cell leukaemia (ATL), 79, 80, 223–4, **223**
- presentation, 223
- prophylaxis, 224
- subtypes, 223
- treatment, 224
- adults
- parainfluenza viruses, 103
- respiratory viral infections (symptoms), **193**
- Advisory Committee on Dangerous Pathogens (ACDP), 200
- Aedes aegypti*, 12, 14, 16, 176, 239, **240**
- Aedes albopictus*, 14, 239
- aerosols, 67, 70, 73, 74, 77, 84, 87, 94, 105, 179, 197
- Afghanistan, 27, 29, 274
- afatoxin, 225
- Africa, 11, 15, 34, 50, 59, 80, 116, 177, 209, 223, 226, 239
- Apollo eye, 203
- measles, 88
- African green monkeys, 175
- age, 74, 75, 101, 108, 150
- airborne route, 87, 105, 138
- alanine aminotransferase (ALT), 24, 31, 35, 40, 207
- Albania, 239
- alcineurin inhibitors, 109
- alcohol, 225
- allograft, 109
- alpha coronaviruses, 67
- Alphavirus* genus, 13, 16–17
- chikungunya, 16
- Eastern equine encephalitis, 16
- miscellaneous examples, 17
- Western equine encephalitis, 16

	Index	297
ALT, <i>see</i> alanine aminotransferase		
amantadine, 269		
action, 266		
dopaminergic side effects, 266		
first anti-influenza agent to be licensed, 266		
viral life-cycle target, 264		
American Association for Study of Liver Diseases (AASLD), 48		
amino acid subunits, 2		
aminotransferase enzymes, 51		
ampicillin, 24		
amplicon, 250, 251		
definition (amplified DNA product), 250		
amprenavir, 272		
anaemia, 112, 113, 186, 220		
anal cancer, 108, 109		
angiotensin-converting enzyme 2 (ACE2), 70		
animal prion disease, 154		
antibiotics, 148, 157, 159		
antibodies, 4		
types, 5		
antibody avidity assays, 247, 248		
antigen detection, 256		
antigen presenting cells (APCs), 4		
antigen-binding receptors, 5		
antigenic drift, 83		
antigenic shift, 83		
antiretroviral drugs, 271		
drug resistance, 272		
mechanism of action, 272		
side effects, 272		
antiretroviral therapy (ART), 59, 60, 61, 63, 64, 65, 288, 289		
antiviral drugs, 1, 109, 263–71		
disadvantage, 263		
further reading, 271		
hepatitis viruses, 267–71, 269		
herpes viruses, 263–6, 268		
respiratory viruses, 266–7, 269		
viral life-cycle targets, 264		
antiviral resistance testing, 252		
aplasia of erythroid cells, 113, 220		
aplastic anaemia, 6		
aplastic crisis, 113, 115		
apoptosis, 4, 224		
definition, 4, 6		
arboviruses, 11–17, 162		
Bunyaviridae family, 17		
dengue virus, 11		
epidemiology, 11		
families, 11		
<i>Flavivirus</i> genus, 11–16		
prevalence, 11		
Togaviridae family, 16–17		
types associated with human illnesses, 12		
arenaviruses: Lassa fever, 174		
Argentina, 16		
arthralgia, 13, 112, 135, 158, 207		
arthropod vectors, 11, 240		
aseptic meningitis, 29		
Asia, 15, 16, 50, 59, 69, 175		
Asia-Pacific region, 27		
asthma, 103, 128, 159, 199		
AstraZeneca adenoviral vector vaccine, 72		
astrocytosis, 156		
astroviruses, 98, 165		
ataxia, 154, 155		
atopic dermatitis, 119		
at-risk groups		
respiratory viral infections (symptoms), 193		
vaccinations, 280		
atypical pneumonia, 157–60		
caused by bacteria rather than viruses, 157		
<i>Chlamydia abortus</i> , 158		
<i>Chlamydia pneumoniae</i> , 158–9		
<i>Chlamydia psittaci</i> , 158		
<i>Coxiella burnetii</i> , 159		
epidemiology, 157		
<i>Legionella pneumophila</i> , 159–60		
<i>Mycoplasma pneumoniae</i> , 157–8		
organisms, vii		
prompt diagnosis		
‘important’, 157		
symptoms, 157		
useful website, 160		
atypical pneumonia (laboratory diagnosis), 160		
serological tests, 160		
summary, 160		
Australasia, 34, 209		
Australia, 154		
avian influenza, 84, 85, 87, 237, 238		
azithromycin, 148, 151, 158		
treatment of chlamydia, 171		
AZT, <i>see</i> zidovudine		
B-cells, 4, 224, 227		
B lymphocytes, 243		
bacteria		
gastroenteritis, 200		
types causing atypical pneumonia, 157		
Ball, Philip M., viii		
baloxavir marboxil, 86, 267		
barefoot, 108, 109		
barrier method (condoms), 36, 66, 82, 109, 148		
bats, 67, 83, 121, 177		
B-cell antigen binding receptor, 5		
beef, 154, 156		
Belgium, 59, 118		
beta coronaviruses, 67		
beta herpesvirus, 74		
beta-lactams, 157		
BHIVA antiretroviral treatment guidelines, 64		
bictegravir, 273		
bilateral cataract, 135		
Biofire		
point-of-care test, 252		
syndromic assays, 253		
birds, 17, 83, 84, 108, 145, 147, 149, 158, 237		
BK virus, 109, 270		
prevention, 109		
treatment, 109		
blindness, 55, 145, 146, 186, 204, 216		
blood cells, 226		
infected, 5		
red, 6, 113		
white, 19, 22, 90		
blood donors, 14, 74, 80, 82, 223		
blood products, 45, 48, 80		
blood science laboratories, 248		
blood transfusions, 113, 149, 154, 155		
blood-borne transmission, 60, 79, 282		
blood-borne viruses (BBVs), 286, 287, 288, 289		
bone marrow transplant recipients, 8, 9, 20, 22, 26, 57, 102, 103, 109, 125, 212, 219		
treatment of ATL, 224		

- bone marrow transplant units:
 PIV infection control, 105
- Bornholm disease, 28, 29
- bovine spongiform encephalopathy (BSE), 156
- clinical, 155
- epidemiology, 153
- prevalence, 154
- route of spread, 154
- brain biopsy, 155
- brain damage, 20, 22
- brain: spongiform degeneration, 153
- Brazil, 16, 224
- Zika virus outbreak (2015), 16
- break bone fever, 14
- breast milk, 182, 185
- breastfeeding, 79, 80, 82, 223, 227
- risk factor for vertical transmission, 184
- brincidofovir, 109, 118, 265, 268
- adenovirus infection (immunocompromised patients), 219
- adenoviruses, 214
- British Association for Study of Liver Disease (BASL), 48
- bronchioalveolar lavage (BAL), 213
- bronchiolitis, 28, 67, 77, 124, 125, 126, 192, 195
- bronchopneumonia, 157
- bronchopulmonary dysplasia, 127, 194, 195
- Bunyaviridae family, 11, 13
- hantaviruses, 179
- Phlebovirus* genus, 17
- Burkitt's lymphoma, 24, 224
- definition, 224
- calcineurin inhibitors, 227
- Caliciviridae family:
 noroviruses, 97
- caliciviruses, 165, 256
- Calne, Sir Roy, 227
- Campylobacter jejuni, 163
- Canada, 16, 118
- cancer, 75, 108, 109, 275
- how caused by viruses, 222
- papillomaviruses, 109
- types caused by oncogenic viruses, 223
- viral malignancies, 222–7
- Candida albicans* (oral, oesophageal thrush), 62
- capillary sequencing, 252
- care homes, 99, 165
- Caribbean, 14, 16, 74, 80, 223
- Castleman's disease, 75, 218
- cats, 68, 117, 149, 156, 234, 238
- cattle, 158, 159, 178, 237, 240
- CD4 cells, 2, 4, 6, 60, 61, *see also* T helper cells
- CD4 count, 61, 65
- CD4 molecule, 60, 273
- CD8 cells, 4, 60
- cell culture, 1
- cell lines (types), 255
- continuous, 255
- primary or semi-continuous, 255
- cell surface, 2
- cell tropism, 2
- cellular lysosomes, 2
- cellular mechanisms, 6
- Centers for Disease Control (CDC, USA), viii
- Central Africa, 42, 44, 50, 118
- Central America, 11, 50, 80, 223
- Central Europe, 50
- central nervous system, 28, 80, 154
- mumps complications, 95
- central nervous system viral infections, 161–4
- further reading, 164
- Guillain-Barré syndrome, 163
- laboratory diagnosis, 163
- post-infectious encephalitis, 162
- subacute sclerosing panencephalitis, 162
- viral encephalitis, 161–2
- viral meningitis, 163
- Central Public Health Laboratory (Colindale), 294
- Cepheid
- enterovirus meningitis test, 253
- point-of-care test, 252
- cerebrospinal fluid (CSF), 56, 95, 164, 243
- cervarix, 109, 225
- cervical cancer, 108, 109, 168, 171, 224–5, 234, 274
- papillomaviruses, 109
- risk factors, 225
- screening programme, 109
- symptoms, 224
- treatment, 109
- vaccines, 225
- cervicitis, 146, 169, 169
- Chad, 50
- chemical defence, 4
- chemokine co-receptors (CCR5 and CXCR4), 60
- chemoprophylaxis, 87, 221
- chemotherapy patients, 125
- chickenpox, 56, 116, 117, 138, 218
- antiviral drugs, 142
- complications, 162
- infection during pregnancy, 139
- laboratory diagnosis, 141
- maternal, 185
- maternal infection within 7 days before due childbirth, 139
- neonatal, 182
- same as 'varicella', 139
- symptoms, 139
- typical rash, 232
- vesicular rash, 138
- vesicular rash (electron microscopy), 255
- chickens, 84, 158, 237
- chikungunya, 13, 16, 240
- childhood
- hepatitis A infection, 30
- hepatitis A vaccination, 32
- vaccinations, 278
- children, 7, 8, 15, 74, 130, 157, 192
- enteroviruses, 27, 28
- hMPV prevalence, 77
- living with HIV, 59
- parainfluenza viruses, 103
- respiratory viral infections (symptoms), 193
- rhinoviruses, 128, 129
- rotavirus A infection, 132
- China, 29, 44, 69, 70, 72, 178, 179, 225
- chlamydia, vii, 145–8, 169, 170
- antibody tests, 170
- clinical, 146–7
- definition, 145

	Index	299
epidemiology, 145		
managment, 148		
no vaccination available, 171		
virus detection, 170		
chlamydia (clinical), 147		
<i>C.abortus</i> , 147		
<i>C.pneumoniae</i> , 147		
<i>C.psittaci</i> , 147		
<i>C.trachomatis</i> , 146–7, 147		
laboratory diagnosis, 147		
LGV, 147		
chlamydia (management), 148		
infection control, 148		
treatment, 148		
<i>Chlamydia abortus</i> , 145, 146, 148		
atypical pneumonia, 158		
clinical, 147		
<i>Chlamydia caviae</i> , 145		
<i>Chlamydia</i> genus, 145		
chlamydia perihepatitis, 146		
<i>Chlamydia pneumoniae</i> , 145, 146, 147, 148, 199		
atypical pneumonia, 158–9		
laboratory diagnosis, 147		
prevalence, 145		
<i>Chlamydia psittaci</i> , 145, 146, 148, 199, 233		
atypical pneumonia, 158		
clinical, 147		
incubation period, 158		
laboratory diagnosis, 147		
prevalence, 145		
route of transmission, 158		
symptoms, 158		
<i>Chlamydia</i> serovars, 145		
<i>Chlamydia</i> species, 145		
infections caused, 146		
<i>Chlamydia trachomatis</i> , 145, 146, 146, 148, 169, 169, 203		
conjunctivitis and keratitis, 204		
genital chlamydia infection, 146		
laboratory diagnosis, 147		
most common bacterial STI (UK), 145		
nasopharyngeal carriage, 146		
ophthalmia neonatorum, 146		
postnatal infection, 188–90		
trachoma, 146		
urethritis, 169		
vertical transmission, 183		
Chlamydiaceae family, 145		
chlamydial pneumonia, 147		
chloramphenicol, 159		
chorioretinitis, 20, 139		
chronic hepatitis, 36, 51		
chronic liver disease, 51, 53		
ciclosporin, 109		
definition, 227		
ciclosporin inhibitors, 227		
cidofovir, 9, 22, 76, 109, 196, 204, 217, 268, 270		
active against DNA viruses, 265		
adenoviruses, 214		
adenoviruses (drug of choice for immunocompromised patients), 219		
treatment of resistant HSV, 218		
cimetidine, 119		
ciprofloxacin, 159		
Civil Aviation Authority (UK), 242		
clarithromycin, 151, 158		
climate change, 239, 240		
clinical		
adenoviruses, 8–9		
central nervous system viral infections, 161		
chlamydia, 146–7		
common cold, 198–9		
ctyomegalovirus, 19–20		
EBV, 24–5		
enteroviruses, 27–8		
gastroenteritis viruses, 165		
glandular fever-type illness, 172		
hepatitis A virus, 31		
hepatitis B virus, 35–9		
hepatitis C virus, 46		
herpes simplex virus, 55–7		
HIV, 61–4		
human herpesviruses (HHV 6–8), 75–6		
human metapneumovirus, 77–8		
human T-cell lymphotropic viruses, 80–1		
influenza viruses, 85		
measles virus, 89–91		
mumps virus, 94–5		
noroviruses, 98–9		
papillomaviruses, 109		
parainfluenza viruses, 102–4		
parvovirus B19, 112–13		
prion protein disease (human), 155		
rabies virus, 122		
respiratory syncytial virus, 125–6		
rhinoviruses, 128–9		
rotaviruses, 131		
rubella virus, 135		
SARS CoV-2, 70–1		
sexually transmitted infections, 168–70		
<i>Toxoplasma gondii</i> infections, 150–1		
transmissible spongiform encephalopathies, 154–6		
varicella-zoster virus, 139–40		
viral hepatitis, 207		
<i>Clinical and Diagnostic Virology</i>		
book aim, vii, 1		
embedded links to websites, vii		
four main sections, vii		
second edition (updated chapters), vii		
target readership, vii		
clinical virologists, 282		
clinical virology, 1		
clinical virology laboratory, <i>see</i> quality control (laboratories)		
clotted blood, 17, 21, 26, 38, 47, 57, 141, 151, 160, 164, 173, 174, 199, 213, 229, 231, 288		
Colindale (North London), 293		
combivir, 271		
common cold, 27, 28, 124, 128, 192, 197–9		
clinical, 198–9		
epidemiology, 197–8		
management, 199		
more likely to be acquired in winter and wet weather ‘myth’, 198		
respiratory virus symptoms in different groups of patients, 193		
viruses, 197		
women and young children most at risk, 197		

300	Index
common cold (clinical), 198–9 laboratory diagnosis, 199, 199 symptoms, 198	coryza, 8, 85, 229
common cold (epidemiology), 197–8 incubation period, 165 infectious period, 198 prevalence, 197 route of spread, 197	coughing, 197, 198, 282
common cold (management) infection control, 199 treatment, 199	Covid-19, 6, 69–73, 192, 293 differential diagnosis, 72 lateral flow tests, 246 management, 72–3 nursing, 73 prevalence, 69 subunit vaccine, 275 treatment, 72 vaccination, 72 vaccination (healthcare workers), 287
Communicable Disease Surveillance Centre (CDSC), 294	Covid-19 (management), 72–3 diagnosis, 72 infection control, 73 treatment, 72
complement fixation test (CFT), 246 diagnostic uses, 247	Covid-19 pandemic, 88, 292, 294, 295 travel industry, 200
condylomata acuminata, 108, 109, <i>see also</i> genital warts	cowpox, 116, 117–18, 234, 238, 274
congenital bilateral cataract, 184	cows, 116, 117, 119, 149, 156, 234
congenital infection, 181 definition, 181	Coxiella burnetii, 199 antibody responses, 159 atypical pneumonia, 159 complications, 159 mortality rate, 159 serological tests, 159 symptoms, 159 treatment, 159
congenital rubella syndrome (CRS), 135, 184 classical triad, 184	coxsackie A, 27, 29, 163, 164 , 203, 204 , 234
congenital varicella syndrome, 139	coxsackie B, 27, 29, 163, 164
congenital viral encephalitis, 162	Creutzfeldt-Jakob disease (CJD) clinical, 155 epidemiology, 153 infection control, 156 route of spread, 154
congenital zika syndrome, 16	Crimean-Congo haemorrhagic fever (CCHF), 175, 178, 234, 240
conjunctivitis, 7, 8, 9, 27, 28, 29, 85, 196, 204 , 229 viral eye infections, 203–4	cruise ships, 7, 70, 98, 100, 165, 200
consultant in communicable disease control (CCDC), 285	Cryptococcus neoformans – meningitis, 62
contact-tracing, 93	Culex mosquitoes, 12–13, 15, 17
control of infection sexually transmitted infections, 171 viral hepatitis, 210	Curran, Martin, viii
cordocentesis, 184	cycle threshold (CT), 250
core mutants, 35	cytokines, 4, 5
corneal inflammation, 204	cytomegalovirus (CMV), 5, 6, 18–22, 31, 62, 151, 162, 163, 169 , 172, 191, 202, 204 , 207, 248, 255, 265, 268
Coronaviridae family, 67	chemoprophylaxis, 221
coronavirus disease 2019, <i>see</i> Covid-19	clinical, 19–20, 208
coronaviruses, 67–73, 192 common cold, 197 definition, 67 four distinct genera, 67 respiratory virus symptoms in different groups of patients, 193 useful websites, 73	congenital infection (diagnosis), 187 congenital infection (severe), 22 definition, 18 epidemiology, 18–19, 208 ganciclovir-resistant (alternative drugs), 22 HIV-AIDS patients, 213 hyperimmune globulin therapy, 185 immunocompromised patients, 212–17 laboratory diagnosis, 173, 173 management, 20–2 postnatal infection, 184–5 regular monitoring, 221 retinitis, 204 symptoms, 172 transplant recipients, 213 vertical transmission, 182 cytomegalovirus (clinical), 19–20 immunocompetent patients, 20 immunocompromised persons, 19 infection in pregnancy, 20 laboratory diagnosis, 20, 20 retinitis, 19 symptoms, 19 cytomegalovirus (epidemiology), 18–19 at-risk groups, 18 incubation period, 18 infectious period, 18 prevalence, 18 route of spread, 18 cytomegalovirus (management), 20–2 infection control, 22 prophylaxis, 22 treatment, 20–2 cytopathic effect (CPE), 254 cytotoxic T-cells, 4, 6, 35

	Index	301
defective RNA virus: hepatitis D, 34, 42	Epstein-Barr virus, 23–6	laboratory diagnosis, 141
<i>Deltaretrovirus</i> genus: human T-cell lymphotropic viruses, 79	herpes simplex virus, 54	measles, 90
dementia, 155	human herpesviruses (HHV 6–8), 74	encephalopathy, 153
demyelinating diseases, 79	poxviruses, 116	endocarditis, 159
dengue fever, 11, 44, 234, 239	varicella-zoster virus, 138	England, 109
most common arbovirus infection (UK), 11	double-stranded RNA viruses: rotaviruses, 130	England and Wales, 51, 294
dengue haemorrhagic fever (DHF), 14, 176, 178–9	doxycycline, 158, 159	entecavir, 40, 210, 219, 269, 271
diagnostic criteria (WHO), 178	drug-injecting equipment, 82	enteric adenoviruses, 7, 8
dengue shock syndrome (DSS), 179	Duncan’s syndrome, 24	differential diagnosis (electronic microscopy), 255
dengue virus, 11–14, 12, 174	East Asia, 179, 226	enteroviruses, 5, 27–9, 163, 192, 196, 203, 204, 243
incubation period, 14	Eastern equine encephalitis (EEE), 16, 17	clinical, 27–8
mortality rate, 14	Eastern equine virus, 13, 240	clinical illnesses, 29
serotypes (four), 14	Eastern Europe, 209, 226	definition, 27
symptoms, 14	Ebola, 175, 208, 234, 238	epidemiology, 27–8
dermatome, 56, 139, 140, 218	haemorrhagic fevers, 177–8	maculopapular skin rashes (laboratory diagnosis), 229
developed countries, 30, 45, 50, 51, 54, 108, 138, 200, 224	<i>Ebolavirus</i> genus: six species, 177	management, 28–9
developing countries, 30, 45, 50, 54, 108, 130, 145, 209, 224	EBV, <i>see</i> Epstein-Barr virus	numbering, 27
dexamethasone, 195	EBV nuclear antigen (EBNA), 26	respiratory virus symptoms in different groups of patients, 193
dialysis, 41, 43, 45, 48, 202, 259	EBNA-1 protein, 224	types, 27
diarrhoea, 9, 130, 131, 132, 165	echoviruses, 27	vesicular skin rashes (laboratory diagnosis), 231
didanosine, 272	ectopic pregnancy, 170	viral rashes, 230, 234
direct-acting antivirals (DAAs), 44, 48, 271	EDTA blood, 17, 22, 26, 63, 151, 164, 173, 174, 213, 229	enteroviruses (clinical), 27–8
classification, 46	efavirenz, 272	laboratory diagnosis, 28
DNA genomes, 1	effector cells, 4	enteroviruses (epidemiology), 27–8
DNA microarray: definition, 251	Egypt, 44, 45	at-risk groups, 27
DNA polymerase enzymes: hepatitis B virus, 34	EIA, <i>see</i> enzyme-linked immunosorbent assays (ELISA)	incubation period, 27
DNA polymerase inhibition, 263	elbasvir, 46, 270, 271	infectious period, 27
DNA vaccines, 275	elderly patients, 68	prevalence, 27
DNA viruses, 222, 265, 266	respiratory viral infections (symptoms), 193	route of spread, 27
usually double-stranded (<i>qv</i>), 1	electron microscopy (EM), 1, 119, 156, 234	enteroviruses (management), 28–9
dogs, 111, 121, 123	limiting factor, 255	infection control, 29
dolutegravir, 273	virus detection (non-molecular technique), 255–6	prophylaxis, 28–9
dorsal route ganglia, 55, 138	elementary bodies (EB): definition, 145	treatment, 28
double-stranded circular DNA: hepatitis B virus, 34	elvitegravir, 273	enzyme-linked immunosorbent assays (ELISA), 209, 254, 257
double-stranded DNA viruses, 7, 265	Emergency Public Health Laboratory Service (UK), 293	advantages, 245
cytomegalovirus, 18–22	encephalitis, 29, 55, 56, 56, 85, 113, 220	automation, 249
	developed from measles, 230	diagnostic uses, 247
		essential steps, 245
		plate, 245
		serological techniques (types), 244–5

302	Index
epidemic myalgia (Bornholm disease), 28	
epidemiology	
adenoviruses, 7–8	
arboviruses, 11–12	
atypical pneumonia, 157	
chlamydia, 145	
common cold, 197–8	
cytomegalovirus, 18–19	
EBV, 23–4	
enteroviruses, 27–8	
gastroenteritis viruses, 165–7	
hepatitis A virus, 30–1	
hepatitis B virus, 34–5	
hepatitis C virus, 44–5	
hepatitis E virus, 50–1	
herpes simplex virus, 54–5	
HIV, 59–61	
human herpesviruses (HHV 6–8), 74	
human metapneumovirus, 77	
human T-cell lymphotropic viruses, 79–80	
influenza viruses, 83–5	
measles virus, 88–9	
mumps virus, 94	
noroviruses, 97–8	
papillomaviruses, 108–9	
parainfluenza viruses, 101–2	
parvovirus B19, 111	
rabies virus, 121–2	
respiratory syncytial virus, 124–5	
rhinoviruses, 128	
rotaviruses, 130–1	
rubella virus, 134	
SARS CoV-2, 69–70	
<i>Toxoplasma gondii</i> infections, 149–50	
transmissible spongiform encephalopathies, 153–4	
varicella-zoster virus, 138–9	
viral hepatitis, 208, 209	
epididymitis, 169	
epididymo-orchitis, 146	
epithelial cells, 4, 101, 109, 124, 226	
Epstein-Barr virus (EBV), 5, 23–6, 31, 62, 151, 163, 169, 172, 202, 207, 248, 269	
associated malignancies, 223	
cancer, 226	
clinical, 24–5, 208	
definition, 23	
epidemiology, 23–4, 208	
HIV-AIDS patients, 213	
immunocompromised patients, 217	
infection, 224, 226, 227	
laboratory diagnosis, 173, 173	
management, 25–6	
not suitable for culture in laboratory, 255	
regular monitoring, 221	
rituximab, 266	
symptoms, 172	
transplant recipients, 213	
Epstein-Barr virus (clinical), 24–5	
complications, 24	
differential diagnosis, 25	
laboratory diagnosis, 26	
symptoms, 24	
Epstein-Barr virus (epidemiology), 23–4	
at-risk groups, 24	
incubation period, 23	
infectious period, 24	
prevalence, 23	
route of spread, 23	
Epstein-Barr virus (management), 25–6	
infection control, 26	
treatment, 25	
Equatorial Guinea, 177	
erythema infectiosum (EI), 112, 230	
skin rash, 112	
erythema multiforme, 158, 231	
erythroid precursor cells, 111, 112	
erythromycin	
children, 148	
chlamydia treatment (drug of choice during pregnancy), 148, 171	
<i>Erythroparvovirus</i> genus: parvovirus B19, 111	
Europe, 30, 34, 50, 59, 69, 74, 80, 88, 175, 224	
European Association for Study of Liver (EASL), 41, 48	
exanthema subitum (sudden rash), 75	
exotic virus infections, 234	
exposure-prone procedures (EPPs), 289, 290	
eye infections, 55, 188	
eye lesions, 56	
eyelid and periocular skin infection, 206	
faecal-oral route, 50, 130, 132, 209, 282, 290	
famciclovir, 57, 142, 206, 265, 268	
treatment of HSV infections, 171	
VZV infections, 218, 231, 233	
fatal familial insomnia (FFI), 155	
fifth disease, 112	
Filoviridae family, 177	
first-void urine (FVU), 147, 170	
Fitz-Hugh-Curtis syndrome, 146, 170	
flaccid paralysis, 28, 29	
Flaviviridae family, 11, 12	
hepatitis C virus, 44	
<i>Flavivirus</i> genus, 11–16, 12	
dengue virus, 11	
Japanese encephalitis virus (JEV), 15	
tick-borne encephalitis virus, 15	
West Nile fever, 14	
yellow fever virus, 14	
Zika virus (ZV), 15	
fluorescein-labelled anti-human antibody, 246	
food, 53, 100	
gastroenteritis viruses, 166	
foscarnet, 22, 57, 76, 204, 217, 268	
active against all herpes viruses, 266	
HSV, 218, 232	
France, 150, 154	
fulminant hepatitis, 31, 35, 39	
clinical emergency, 31	
fulminant liver failure, 51, 219	
fusion inhibitors (FIs), 273	
gamma herpesvirus, 74	
ganciclovir, 22, 76, 185, 204, 268	
CMV, 20, 213, 217	
mechanism of action, 265	
resistance, 265	

	Index	303
viral life-cycle target, 264 gardasil, 109, 225 gastric flu, 85 gastroenteritis, 97, 98, 130, 131, 132 multiplex PCR test, 251 travel-related, 200 gastroenteritis viruses, 165–7, 256 clinical, 165 electron micrograph photographs, 166 epidemiology, 165–7 useful website, 167 gastroenteritis viruses (epidemiology), 165–7 food-borne infection, 166 infection control, 167 laboratory diagnosis, 166 noroviruses, 165 other enteric viruses, 165 prophylaxis, 167 rotaviruses, 165 treatment, 167 vaccine, 167 gastrointestinal route, 282 gelatin particle agglutination test (GPAT), 246, 247 genital cancers, 108 genital infection, 54, 145 chlamydia, 146 in pregnancy, 170 genital lesions, 168, 186, 188 non-vesicular or non-ulcerative, 168 vesicular or ulcerative, 168, 169 genital tract infections, 168–71 genital warts, 108, 109, 168, 170, 171, 225, 234 cryosurgery with liquid nitrogen, 171 incubation period, 108 men, 109 papilloma virus vaccines, 234 same as condylomata acuminata, 109 virus detection, 170 women, 109 genotypic resistance test, 63, 64 Germany, 118, 154, 177 Gerstmann–Straussler–Scheinker (GSS) disease, 155	giant cell pneumonitis, 90 gingivostomatitis, 55 glandular fever, 24, 25, 217 definition, 172 glandular fever–type illness, 172–3 clinical, 172 differential diagnosis, 172 laboratory diagnosis, 173 symptoms, 172 glecaprevir, 47, 210, 270, 271 glycoproteins, 153 goats, 119, 148, 149, 156, 158, 159, 178, 238, 240 gonococcal infection, 169 Graham 293 cells, 255 adenovirus cytopathic effect, 255 uninfected, 255 granzymes, 4 Gray, Jim, viii grazoprevir, 47, 270, 271 Green Book hepatitis B chapter, 41, 42 immunisation, 43 Gregg, Sir Norman, 135, 184 Guandong Province (China), 68 Guillain–Barré syndrome, 157 CNS viral infections, 163 Guyana, 16 haemagglutination, 244 haemagglutination inhibition tests (HAIs), 246 haemagglutinin (HA), 2, 83, 84, 134 definition, 192 haemagglutinin type 1 and neuraminidase type 1 (H1N1), 86, 192, 266 influenza A pandemic (1918), 84 haemagglutinin type 3 and neuraminidase type 2 (H3N2) virus, 192 haematopoietic stem cell transplant recipients, 195, 196 haematopoietic stem cells, 4, 5, 125, 219, 226 haemoglobin, 113 haemolytic anaemia, 113, 115, 157 haemophagocytic lymphohistiocytosis (HLH), 24	haemorrhagic conjunctivitis, 27 haemorrhagic cystitis, 109, 220 haemorrhagic fever viruses, 174 differential diagnosis, 174 endemic countries, animal host, treatment, whether person-to-person spread, 175 specimens for diagnosis, 174–9 useful websites, 174–9 haemorrhagic fever with renal syndrome (HFRS), 176, 179–80 haemorrhagic fevers, 174–80 Crimean-Congo haemorrhagic fever, 178 dengue haemorrhagic fever, 178–9 Ebola, 177–8 Lassa fever, 174–7 Marburg disease, 177 travel-related, 200 haemorrhagic rashes, 228, 234 hairly leukoplakia, 217 hand, foot and mouth disease, 27, 28, 29, 29, 234 handwashing, 33, 73, 99, 105, 127, 137, 152, 283, 284 hantavirus cardiopulmonary syndrome (HCPS), 179 hantavirus pulmonary syndrome (HPS), 176, 179, 238 hantaviruses, 174, 238 species, 179 types, 179 HCWs, <i>see</i> healthcare workers Health Protection Agency (HPA), 294 healthcare workers, 45, 48, 60, 61, 86, 87, 93, 123, 137 immunocompromised, 287 infected with viruses (management), 289–90 infection and outbreak control, 290–1 occupational health, 286–91 pregnant, 287 vaccination (bacteriological vaccine-preventable diseases), 287 HeLa (human cervical cancer cell line), 255

304	Index
helper T-cells, 6, 60	telbivudine, 271
Hepadnaviridae family:	tenofovir, 267
hepatitis B virus, 34–42	hepatitis B virus (clinical),
hepatitis, 113, 169, 219, 220	35–9
tests, 210	acute hepatitis B, 35
travel-related, 200	acute infection (serological
hepatitis A virus (HAV), 30–3,	markers), 37
166, 207, 276	chronic hepatitis B, 36
clinical, 31	laboratory diagnosis, 38
clinical and epidemiological	neonatal hepatitis B, 37
features, 208	hepatitis B virus
definition, 30	(epidemiology), 34–5
epidemiology, 30–1, 209	at-risk groups, 36
IgM, 241	incubation period, 34
infection and outbreak	infectivity, 35
control (healthcare	prevalence, 34
setting), 290	route of spread, 34
laboratory markers and	hepatitis B virus
clinical interpretation, 209	(management), 39–42
management, 31–3, 210	prophylaxis, 41–2
travel-related, 200	treatment, 39–41
treatment, 211	vaccines, 41
useful website, 33	vaccines (groups with
hepatitis A virus (clinical), 31	poorer response), 41
acute hepatitis, 31	vaccines (post-exposure), 42
complications, 31	vaccines (priority groups,
laboratory diagnosis, 32	UK), 41
laboratory investigations, 31	hepatitis B virus (prophylaxis),
hepatitis A virus	41–2
(epidemiology), 30–1	post-exposure, 42
at-risk groups, 31	pre-exposure, 41–2
incubation period, 30	hepatitis B virus (treatment),
infectious period, 30	39–41
prevalence, 30	acute infection, 39
route of spread, 30	chronic infection, 40–1
hepatitis A virus	hepatitis B virus DNA (HBV
(management), 31–3	DNA), 35, 36, 40, 41, 42
infection control, 33	serological markers in
prophylaxis (post-	blood, 39
exposure), 32	hepatitis C virus (HCV), 1, 31,
prophylaxis (pre-exposure),	44–9, 202, 207, 225, 227,
31	248, 259, 270, 286, 287,
treatment, 31	288, 289, 291
vaccines, 31	antibody reactive results,
hepatitis B antibody (anti-	259
HBe), 40, 40, 41	antibody test, 46
serological markers in	antiviral drugs, 271
blood, 39	associated malignancy, 223
hepatitis B core antibody	clinical, 46
(anti-HBc), 34, 41, 259	clinical and epidemiological
hepatitis B core antigen, 34	features, 208
hepatitis B e antigen (HBeAg),	clinical course of infection,
34, 35, 37, 39–40, 40, 41,	46
42	definition, 44
chronic infection	epidemiology, 44–5, 209
(serological markers), 37	genotypes, 44
hepatitis B immunoglobulin	
(HBIG), 42, 288	
hepatitis B surface antibody	
(anti-HBs), 41	
serological markers in	
blood, 39	
hepatitis B surface antigen	
(HBsAg), 34, 35, 36,	
39–40, 40, 41, 42, 219,	
241, 258, 275, 288, 289	
hepatitis B surface antigen	
patients (negative)	
HBV markers (clinical	
interpretation), 38, 41	
hepatitis B surface antigen	
patients (positive), 38, 40	
hepatitis B virus (HBV), 6, 31,	
42, 202, 207, 225, 227,	
241, 258, 259, 269, 276,	
286, 287, 288, 289, 291	
associated malignancy, 223	
chemoprophylaxis, 221	
clinical, 35–9	
clinical and epidemiological	
features, 208	
epidemiology, 34–5, 209	
immunocompromised	
patients, 219	
infection, 6, 225	
laboratory markers and	
clinical interpretation, 209	
management, 39–42, 210	
needlestick transmission	
inquiries, 252	
reactivation, 219	
regular monitoring, 221	
serological markers in blood	
(at different stages of	
infection), 39	
subunit vaccine, 275	
transplant recipients, 214	
travel-related, 200	
treatment, 211	
vaccination, 34, 225, 274,	
275	
vaccination (healthcare	
workers), 286	
vertical transmission, 183	
hepatitis B virus (antiviral	
drugs), 267–71	
adefovir, 267	
entecavir, 271	
interferon alpha, 267	
lamivudine, 267	
pegylated interferon alpha,	
267	

	Index	305
laboratory markers and clinical interpretation, 209	epidemiology, 50–1, 209	lesions, 140, 170
management, 46–8, 210	genotypes, 50	management, 57–8
RNA virus able to induce malignancy, 222	immunocompromised patients, 219	postnatal infection, 186–8
serotypes, 44	laboratory markers and clinical interpretation, 209	type one, 54, 161, 162, 170
treatment, 211	management, 52, 210	type two, 54, 161, 162, 163, 170
vertical transmission, 183	transplant recipients, 214	typical skin rash, 232
hepatitis C virus (clinical), 46	treatment, 211	vertical transmission, 182
laboratory diagnosis, 46, 46–7	zoonotic infection spread by direct contact, 238	vesicular skin rashes (laboratory diagnosis), 231
symptoms, 46	hepatitis E virus (clinical)	viral encephalitis, 161
hepatitis C virus	acute hepatitis, 51	viral rashes, 231
(epidemiology), 44–5	chronic hepatitis, 51	herpes simplex virus (clinical), 55–7
at-risk groups, 45	infection (laboratory diagnosis), 52	differential diagnosis, 56
incubation period, 45	laboratory diagnosis, 52	infection (laboratory diagnosis), 56
infectious period, 45	hepatitis E virus	infection (primary), 55
prevalence, 44	(epidemiology), 50–1	laboratory diagnosis, 56
hepatitis C virus	at-risk groups, 51	symptoms, 55–6
(management), 46–8	incubation period, 51	herpes simplex virus
infection control, 48	infectious period, 51	(epidemiology), 54–5
prophylaxis, 48	prevalence, 50	at-risk groups, 54
treatment, 46–8	route of spread, 50	incubation period, 54
useful websites, 48	hepatitis E virus	infectious period, 54
hepatitis C virus (routes of spread), 44–5	(management)	prevalence, 54
blood and blood products, 44	infection control, 53	route of spread, 54
body piercing and tattooing, 45	prophylaxis, 52	herpes simplex virus
iatrogenic, 45	treatment, 52	(management), 57–8
occupational, 45	hepatitis viruses, 207, 243	infection control, 58
PWID, 44	antiviral drugs, 267–71	prophylaxis, 57
sexual, 45	cannot be grown in cell culture, 255	treatment, 57
vertical (mother to baby), 45	hepatocellular carcinoma, 36, 40, 46, 225, 274	herpes viruses, 6, 162
hepatitis D virus (HDV), 207	hepatocytes, 6, 35	electron micrograph, 142
‘cannot replicate in humans in absence of HBV’, 34	hepatomegaly, 24, 184	electron microscopy (limiting factor), 255
clinical and epidemiological features, 208	hepatosplenomegaly, 20, 80, 135, 151, 184, 224	no vaccination available, 171
co-infection versus super-infection, 42	hepatotropic viruses, 207	herpes viruses (antiviral drugs), 263–6
definition, 34	<i>Hepatovirus</i> genus: hepatitis A virus, 30–3	aciclovir, 263–4
laboratory markers and clinical interpretation, 209	herpangina, 29	brincidofovir, 265
management, 210	definition, 28	cidofovir, 265
mortality, 42	herpes simplex virus (HSV), 6, 54–8, 62, 168, 169, 204, 268	famciclovir, 265
prevalence, 42	aciclovir treatment, 263	foscarnet, 266
useful websites, 43	clinical, 55–7	ganciclovir, 265
vaccination, 43	definition, 54	peniclovir, 265
hepatitis delta virus (HDV), 42	encephalitis, 188	rituximab, 266
hepatitis E virus (HEV), 1, 50–3, 166, 200, 207	epidemiology, 54–5	valaciclovir, 265
clinical and epidemiological features, 208	immunocompromised patients, 217–18	valganciclovir, 265
	keratitis, 203	Herpesviridae family
		cytomegalovirus, 18–22
		Epstein–Barr virus, 23–6
		hepatitis E virus, 50
		herpes simplex virus, 54

- Herpesviridae family (cont.)
 human herpesviruses (HHV 6–8), 74
 varicella-zoster virus, 138
 heterophile antibody, 173
 high pathogenic avian influenza A viruses (HPIAV), 84
 high-security facility, 174
 histology, 122, 155, **206**, **214**, **216**
 HIV RNA (viral load), 63, 65
 HIV RNA NAAT (usually PCR), 63
 HIV-AIDS, 19, **21**, 75, 212
 HHV-6 reactivations, 218
 HIV-AIDS patients, 57, 75, 109, 204, 212
 CMV symptoms, 216
 EBV, 217
 virus infections, 215
 Hodgkin's lymphoma, 225
 horses, 15, 16, 17, **240**
 hospitalisation, 72, 77, 101, 124, 125, 130, 132
 hospitals, 22, 87, 98, 99, 105, 157, 165, 196, 283, 284
 host factors, 5, 6
 HTLV-1-associated myelopathy (HAM), 79, 80
 human coronaviruses, 67–73
 human herpesviruses (HHV 4), *see* Epstein-Barr virus
 human herpesviruses (HHV 6), 162, 163
 human herpesviruses (HHV 6–7), **229**
 viral rashes, 231
 human herpesviruses (HHV 6–8), 74–6
 clinical, 75–6
 definition, 74
 epidemiology, 74
 immunocompromised patients, 218
 management, 76
 transplant recipients, **214**
 human herpesviruses HHV 6–8 (clinical)
 laboratory diagnosis, 76
 symptoms, 75
 human herpesviruses HHV 6–8 (epidemiology), 74
 at-risk groups, 74
 prevalence, 74
 route of spread, 74
 human herpesviruses HHV 6–8 (management), 76
 infection control, 76
 prophylaxis, 76
 treatment, 76
 human herpesviruses (HHV 8), 226
 associated malignancy, **223**
 HIV-AIDS patients, 213
 human immunodeficiency virus (HIV), 1, 2, 5, 6, 59–66, **169**, 172, 190, 202, 246, 248, 286, 287, 288, 289, 291
 antiviral resistance testing, 252
 clinical, 61–4
 constantly mutating, 6
 definition, 59
 epidemiology, 59–61
 groups and subtypes, 59
 infection (laboratory diagnosis), **64**
 laboratory diagnosis, **173**
 management, 64–6
 not suitable for culture in laboratory, 255
 serological markers (diagrammatic representation), 63
 useful websites, 66
 vertical transmission, **183**
 human immunodeficiency virus (clinical), 61–4
 acute HIV seroconversion illness, 61
 AIDS, 61–2
 chronic HIV seroconversion illness, 61
 laboratory diagnosis, 62–3
 neonates, 63
 human immunodeficiency virus (epidemiology), 59–61
 at-risk groups, 61
 incubation period, 60
 infectious period, 61
 pathogenesis, 60
 prevalence, 59
 routes of spread, **60**, 61
 human immunodeficiency virus (management), 64–6
 infection control, 66
 prophylaxis, 65
 treatment, 64–5
 human immunodeficiency virus (prophylaxis)
 post-exposure, 65
 pre-exposure, 65
 human immunodeficiency virus (treatment), 64–5
 opportunistic infections and malignancies, 65
 human metapneumovirus (hMPV), 77–8
 clinical, 77–8
 definition, 77
 epidemiology, 77
 respiratory virus symptoms in different groups of patients, **193**
 human metapneumovirus (clinical), 77–8
 infection control, 78
 laboratory diagnosis, 78
 symptoms, 77
 human metapneumovirus (epidemiology), 77
 at-risk groups, 77
 incubation period, 77
 infectious period, 77
 prevalence, 77
 route of spread, 77
 human normal immunoglobulin (HNIG), 32, 92, 290
 human papillomaviruses (HPVs), 108, 227
 associated malignancies, **223**
 definition, 108
 infection, 224
 vaccines, 225
 human polyomavirus 1, *see* BK virus
 human polyomavirus 2, *see* JC virus
 human simplex virus (HSV), 163, 170, 233, 265
 chemoprophylaxis, 221
 HIV-AIDS patients, 213
 transplant recipients, **213**
 human T-cell lymphotropic virus 1 (HTLV-1), 79–81, 223, 227
 associated malignancy, **222**, **223**
 clinical, 80–1
 epidemiology, 79–80
 management, 81
 vertical transmission, **183**

	Index	307
human T-cell lymphotropic virus 2 (HTLV-2), 79, 222		
clinical, 81		
epidemiology, 79–80		
human T-cell lymphotropic virus 3 (HTLV-3), 79		
‘no specific illnesses’, 79		
human T-cell lymphotropic virus 4 (HTLV-4), 79		
human T-cell lymphotropic viruses (HTLVs), 79–82		
clinical, 80–1		
definition, 79		
epidemiology, 79–80		
management, 81		
types, 79		
human T-cell lymphotropic viruses (clinical), 80–1		
laboratory diagnosis, 81		
human T-cell lymphotropic viruses (epidemiology), 79–80		
at-risk groups, 80		
incubation period, 80		
infectious period, 80		
prevalence, 80		
route of spread, 79		
human T-cell lymphotropic viruses (management), 81		
infection control, 82		
prophylaxis, 81		
hydrocephalus, 139, 151, 186		
hydrophobia, 122		
hydrops foetalis, 112, 182, 186, 228		
parvovirus B19 treatment, 113		
hydroxychloroquine, 159		
hygiene, 27, 30, 31, 133, 146, 209, 283		
hypercalcaemia, 80, 224		
hypoplasia, 113, 139, 220		
iatrogenic CJD, 155, 156		
iatrogenic transmission, 43, 48		
immune response to viruses, 3–4		
immunocompetent patients, 20, 21, 57, 113, 161, 268		
immunocompromised children, 9, 126, 139, 195		
immunocompromised patients, 10, 19, 21, 51, 55, 57, 58, 70, 78, 85, 119, 124, 125, 195		
categories, 212		
CMV treatment, 20		
HIV-AIDS (virus infections), 215		
measles, 90		
parvovirus B19, 113		
<i>Toxoplasma</i> infection, 150		
virus infections, 213		
VZV, 290		
immunocompromised patients (management of virus infections), 220–1		
monitoring, 221		
prophylaxis, 221		
treatment, 221		
immunocompromised patients (virus infections), 212–21		
adenoviruses, 218–19		
cytomegalovirus, 212–17		
Epstein–Barr virus, 217		
further reading, 221		
hepatitis B virus, 219		
hepatitis E virus, 219		
herpes simplex virus, 218		
HHV68, 218		
management, 220–1		
papillomaviruses, 220		
polyomaviruses, 220		
respiratory viruses, 219		
varicella-zoster virus, 218		
immunofluorescence tests (IFTs), 247		
advantage and disadvantage, 246		
purpose, 246		
immunoglobulins, 5, 123, 284		
IgA, 5, 243		
IgG, 5, 21, 113, 241, 243, 244, 248		
IgM, 5, 21, 241, 243, 244		
IgM antibody, 174, 241		
immunosuppressed persons, 56, 75, 141		
EBV, 25		
live vaccines ‘generally contraindicated’, 274		
measles, 92		
immunosuppression reduction: main objective, 109		
immunosuppressive drugs, 52, 109, 212, 216, 217, 227		
inactivated virus vaccines, 275		
inclusion conjunctivitis, 146		
India, 50, 60, 72, 178, 209		
Indian Ocean, 16		
indinavir, 272		
viral life-cycle target, 264		
infants, 75, 77, 108, 124, 127, 130		
measles, 92		
protection from RSV infection, 127		
infected blood, 5, 42, 44, 80, 178, 209		
infection control, 282–5		
adenoviruses, 10		
chlamydia, 148		
common cold, 199		
cytomegalovirus, 22		
enteroviruses, 29		
Epstein–Barr virus, 26		
gastroenteritis viruses, 167		
hepatitis A virus, 33		
herpes simplex virus, 58		
HIV, 66		
human herpesviruses HHV 6–8, 76		
human metapneumovirus (clinical), 78		
human T-cell lymphotropic viruses, 82		
influenza viruses, 87		
measles, 92		
mumps, 96		
noroviruses, 99–100		
notifiable infections, 285		
papillomaviruses, 109		
parainfluenza viruses, 105		
parvovirus B19, 115		
post-exposure prophylaxis, 284		
pox viruses, 120		
precautions, 283–5		
rabies virus, 123		
respiratory syncytial virus, 127		
respiratory viral infections, 196		
rhinoviruses, 129		
rotaviruses, 132		
rubella virus, 137		
<i>Toxoplasma gondii</i> infections, 152		
transmissible spongiform encephalopathies, 156		
varicella-zoster virus, 143		
viruses (route of entry and spread), 282–3		
infection control (precautions), 283–5		
enteric precautions, 284		

308	Index
infection control (precautions) (cont.) - highly dangerous pathogens, 284 - in community, 283 - in hospitals, 283 - respiratory precautions, 283 - universal precautions, 283	possess haemagglutinin antigen, 246 RNA genome, 83 types (four), 83
infection outbreak committee, 285	influenza viruses (clinical), 85
infection outbreaks, 284–5 - control, 285 - investigation, 284	differential diagnosis, 85
infection: latent versus chronic, 6	laboratory diagnosis, 86
infectious diseases physicians, 200	symptoms, 85
infectious mononucleosis (IM), 24, 172	influenza viruses (epidemiology), 83–5
inflammatory cytokine syndrome, 75	at-risk groups, 85
influenza, 6	incubation period, 85
immunocompromised patients, 219	infectious period, 85
infection and outbreak control (healthcare setting), 290	prevalence, 84
respiratory viral infections, 192–5	route of spread, 84
respiratory virus symptoms in different groups of patients, 193	influenza viruses (management), 86–7
subunit vaccine, 275	infection control, 87
vaccination (healthcare workers), 287	prophylaxis (post-exposure), 87
influenza A, 83–4, 85, 204	prophylaxis (pre-exposure), 86
Cepheid test, 253	treatment, 86
immunofluorescence tests, 244	inguinal lymphadenopathy, 145, 169
influenza A virus, 6, 192, 266, 269, 276	innate immune response, 4
influenza B, 83, 84, 85, 86	definition, 3
Cepheid test, 253	interferon, 6
influenza B virus, 192, 266, 269, 276	interferon alpha, 269
influenza C, 83	ATL (leukaemic forms), 224
influenza D, 83	treatment of chronic hepatitis B and C infections, 267
influenza vaccination, 72, 84	viral life-cycle target, 264
clinical, 85	interleukin 6 (IL-6), 5
common cold, 197	international standards
definition, 83	ISO 15189 (2022), 260, 261
epidemiology, 83–5	ISO 22870 (2016), 260
further reading, 87	intradermal (I/D) route, 123
management, 86–7	intramuscular (I/M) route, 123
	intravenous drug users (IDUs), 42, 248, 288
	intravenous immunoglobulin (IVIG), 92, 109
	Italy, 16, 239
	Janssen adenoviral vector vaccine, 72
	Japan, 79, 80, 223
	Japanese encephalitis, 12, 239, 276
	Japanese encephalitis virus (JEV), 15
	mortality, 15
	symptoms, 15
	transmission, 15
	vaccines, 15
	jaundice, 14, 20, 24, 30, 31, 35
	JC virus, 109, 110, 162, 220
	HIV-AIDS patients, 213
	Jenner, Edward, 117, 274
	Johnson and Johnson
	adenoviral vector vaccine, 72
	Joint Committee on Vaccination and Immunisation (JCVI, UK), 109, 225
	Junin virus, 208
	Kaposi's sarcoma, 62, 74, 75, 214, 216, 218, 223, 226
	definition, 226
	types, 226
	Kenya, 17
	keratitis, 204, 204
	keratoconjunctivitis, 55, 204
	ketolides, 160
	kidney transplant recipients, 109
	kidneys, 109, 110, 224, 268
	killed virus vaccines, 275, 276
	kissing disease, 23
	Koplik's spots, 8, 89, 218
	Korea, 179
	Kudesia, Goura, v
	kuru, 153, 155, 156
	Kyasanur Forest virus, 208
	laboratory accreditation, 260–1
	laboratory computer, 259
	laboratory quality control, 258–60
	laboratory request form for specimen errors, 259
	laboratory test reporting computer, 259
	laboratory tests, 259
	laboratory: sending specimens to, 241–2
	laboratory-users' manual, 241
	lamivudine, 40, 269, 271, 272
	first-line anti-HBV agent, 267
	laryngeal warts, 109
	laryngitis, 198
	Lassa fever, 174–7, 234
	endemic countries, animal host, treatment, whether person-to-person spread, 175

- www.cambridge.org

- measles virus (cont.)
 - epidemiology, 88–9
 - maculopapular skin rashes (laboratory diagnosis), 229
 - management, 91–3
 - useful websites, 92, 93
- measles virus (clinical complications), 90
- encephalitis, 90
- secondary bacterial infection, 90
- measles virus (clinical), 91
- complications, 90
- immunocompromised patients, 90
- laboratory diagnosis, 91
- symptoms, 89
- symptoms (WHO manual), 89
- measles virus (epidemiology), 88–9
 - at-risk groups, 89
 - incubation period, 89
 - infectious period, 89
 - prevalence, 88
 - route of spread, 88
- measles virus (management), 91–3
 - infection control, 92
 - prophylaxis (post-exposure), 92
 - prophylaxis (pre-exposure), 91
 - treatment, 91
- measles-like symptoms, 8
- medical tourism infections, 200
- Mediterranean, 226
- men who have sex with men (MSM), 65, 65, 108, 109, 118, 170, 234, 288
- meningitis, 28, 55, 56, 95, 163, 196
 - can be caused by HSV and VZV, 161
 - laboratory diagnosis, 141, 164
- meningoencephalitis, 12, 15, 28, 95, 147, 151, 161, 178, 219
- Merkel cell cancer, 108, 226
- Merkel cell polyomavirus, 226
 - associated malignancy, 223
- messenger RNA (mRNA) vaccines, 275, 276
- Metapneumovirus* genus:
 - human metapneumovirus, 77
- Mexico, 16, 50
- mice, 149
- microarrays, 251
- microcephaly, 135, 139, 184
- microorganisms, 3
- microscopic DNA spots (probes), 251
- Middle East, 50, 226
- Middle East respiratory syndrome (MERS), 1, 69
 - clinical presentation, 69
 - diagnostic tests, 69
 - incubation period, 69
 - mortality rate, 69
 - nursing, 69
 - symptoms, 69
- Middle East respiratory syndrome coronavirus (MERS-CoV), 67, 69, 237
 - route of spread, 69
 - zoonotic infection spread by direct contact, 238
- milker's nodule, 116, 118, 119, 234
- MMR vaccine, 88, 92, 96, 136, 184, 287, 291
- Moderna mRNA vaccine, 72
- modified vaccinia Ankara (MVA-BN) vaccine, 117
- mogamulizumab: relapsed treatment of ATL (Japan), 224
- Moldova, 42
- molecular diagnostic techniques, 1, 249
- molecular techniques, 250–3
 - benefits, 250
 - definition, 250
 - loop-mediated isothermal amplification, 251
 - microarrays, 251
 - next-generation sequencing, 252
 - nucleic acid sequencing, 252
 - point-of-care tests, 252
 - polymerase chain reaction, 250–1
 - transcription-mediated amplification, 251
 - whole genome sequencing (determination of DNA fingerprint), 252
- molecular testing, 241
- molluscipoxvirus, 116
- molluscum contagiosum, 116, 119, 168, 170, 206
 - definition, 234
 - skin rash, 236
 - usually self-limiting condition, 171
- molnupiravir, 267
- Mongolia, 42
- monkeypox, 116, 117, 118–19, 120, 140, 234, 266, 277
 - now referred to as 'mpox', 118
 - typical lesions, 235
 - zoonotic infection spread by direct contact, 238
- monkeys, 14, 16, 59, 79, 110, 116, 121
- monoclonal antibodies, 246
- monospot test, 173
- Morbillivirus* genus: measles virus, 88
- mosquitoes, 11, 16, 17, 239
- mother-to-child transmission, *see* vertical transmission
- mouth and lips, 55
- mucus membrane infections, 109
 - papillomaviruses, 109
- multi-mammate rat (*Mastomys natalensis*), 175, 177
- multiplex PCR test, 251
- multisystem inflammatory syndrome in children (MIS-C), 71
- mumps virus, 94–6, 163, 276
 - clinical, 94–5
 - definition, 94
 - epidemiology, 94
 - management, 96
 - vaccination (healthcare workers), 287
- mumps virus (clinical), 94–5
 - acute parotitis, 94
 - complications, 95
 - differential diagnosis, 95
 - laboratory diagnosis, 95
- mumps virus (epidemiology), 94
 - at-risk groups, 94
 - incubation period, 94
 - infectious period, 94
 - prevalence, 94
 - route of spread, 94

	Index	311
mumps virus (management)		
infection control, 96		
prophylaxis, 96		
treatment, 96		
mumps, measles, rubella		
vaccine, <i>see</i> MMR		
vaccine		
myalgia, 8, 14, 15, 16, 150, 158,		
177, 192		
mycobacterium avium		
complex, 62		
mycobacterium tuberculosis,		
62		
Mycoplasma pneumoniae,		
199, 233		
atypical pneumonia, 157–8		
myelopathy, 79, 80		
myocarditis, 29, 85, 113, 186,		
219, 220		
nasopharyngeal aspirate, 246		
nasopharyngeal carcinoma,		
226		
nasopharyngeal infection, 190		
nasopharynx, 103		
National Chlamydia Screening		
Programme (NCSP, UK),		
148		
natural killer (NK) cells, 4		
negri bodies, 122		
nelfinavir, 272		
neonates, 18, 27, 63, 162, 163,		
248		
chickenpox threat, 141, 142		
conjunctivitis, 146		
death, 20		
enteroviruses, 28		
hepatitis B vaccination, 37		
herpes, 55, 56, 56		
herpes simplex infection,		
170, 182, 188, 232		
nephritis, 109		
nephropathica epidemica, 179		
nephropathy, 109, 220		
nested PCR test, 250		
neuraminidase (NA), 83, 266		
definition, 192		
neuraminidase inhibitor		
(NAI) drugs, 86		
neuritis, 204		
neurological abnormalities,		
139		
neutralisation tests, 244, 248		
nevirapine, 272		
New Guinea, 153		
New World hantaviruses, 179		
next-generation sequencing,		
252		
disadvantage, 252		
Nigeria, 50, 174		
nipah virus, 237, 239		
nirmatrelvir, 72, 195		
non-enveloped DNA viruses		
human papillomaviruses		
(HPV), 108		
polyomaviruses, 108		
non-nucleoside reverse		
transcriptase inhibitors		
(NNRTIs), 271, 272		
non-polio myelitis, 28, 29		
non-serum samples: use for		
antibody tests, 248		
non-specific urethritis (NSU),		
146		
non-structural proteins, 271		
non-viral pathogens, vii		
norovirus genogroup I (GI),		
97		
norovirus genogroup II (GII),		
97		
Norovirus genus, 97		
noroviruses, 282, 284		
cannot be grown in cell		
culture, 255		
clinical, 98–9		
differential diagnosis		
(electronic microscopy),		
255		
electron micrograph, 99		
epidemiology, 97–8		
gastroenteritis, 165, 200		
genogroups and genotypes,		
97		
management, 99–100		
outbreaks, 165		
noroviruses (clinical), 98–9		
differential diagnosis, 98		
laboratory diagnosis, 99		
outbreaks, 98		
symptoms, 98		
noroviruses (epidemiology),		
97–8		
at-risk groups, 98		
incubation period, 98		
infectious period, 98		
prevalence, 98		
route of spread, 97		
noroviruses (management),		
99–100		
infection control, 99		
prevention, 99		
treatment, 99		
North Africa, 17, 50, 69		
North America, 50, 59, 69, 224		
Northern Territory		
(Australia), 14		
Norwalk virus, 97		
novoviruses, 97–100		
definition, 97		
nucleic acid amplification tests		
(NAATs), 9, 9, 20, 21, 28,		
47, 52, 56, 56, 72, 81, 86,		
91, 95, 147, 147, 170, 209,		
234, 243, 250, 254, 257,		
<i>see also</i> molecular		
techniques		
NAAT (RT-PCR), 99		
nucleic acid sequencing, 252		
nucleocapsid, 2		
nucleocapsid proteins (NPs),		
83		
nucleoside analogues (NAs),		
41, 219, 263, 265, 266,		
267, 272		
nucleoside reverse		
transcriptase inhibitors		
(NRTIs), 271, 272, 289		
nursing, 33, 178		
nursing homes, 70, 98, 125,		
130, 165, 196		
obligate intracellular gram		
negative bacteria		
chlamydia, 145		
occupational health, 286–91		
further reading, 291		
healthcare workers infected		
with viruses		
(management), 289–90		
infection and outbreak		
control (healthcare		
setting), 290–1		
needlestick and sharps		
injuries, 287–9		
post-exposure follow-up,		
289		
pre-employment health		
check, 286		
vaccination, 278, 286–7		
ocular adenoviruses, 8		
ofloxacin, 159		
Old World hantaviruses, 179		
ombitasvir, 46, 270, 271		
oncogene: definition, 222		
oncogenic: definition, 222		
oncoviruses, 75		
Ontario, 16		
ooocysts, 149		

- oophoritis, 95, 146
 ophthalmia neonatorum, 146,
 146–7, 183, 188
 opsonisation: definition, 5
 orchitis, 94, 95, 169
 orf virus, 116, 118, 119
 definition, 234
 zoonotic infection spread by
 direct contact, 238
 organ donors, 45, 82, 259
 organ transplant recipients,
 108, 109, 149, 212, 218,
 219
 Toxoplasma infection, 150
 organ transplantation, 8, 35,
 226
 Orthomyxoviridae family, 83
 orthopox viruses, 119
 orthopoxvirus, 116
 oseltamivir, 6, 86, 87, 204, 266,
 269, 290
 treatment of influenza, 195
 viral life-cycle target, 264
 otitis media, 90, 103, 129
 outer envelope protein E1, 134
 outer proteins, 34
 oxytetracycline: treatment of
 chlamydia, 171
- P antigens, 111
 paired sera, 241
 paired serological
 investigations, 242
 Pakistan, 27, 29, 274
 palivizumab, 126, 195, 269
 prophylaxis of RSV
 infection, 267
 viral life-cycle target, 264
 pandemic preparedness
 advance risk assessment, 292
 effective surge capacity
 ‘vital’, 294
 illness and death
 (minimisation), 292
 prescribing regulations
 (modification), 293
 surge plans, 292
 surveillance and modelling,
 292
 transmission risk
 (reduction), 292
 vaccination, 292
 pandemic strategies
 (response)
 assessment, 293
 detection, 293
 escalation, 293
 recovery, 293
 treatment, 293
- Papillomaviridae family, 108
 papillomaviruses, 108–9, 168,
 169, 170, 206, 234, 276
 cannot be grown in cell
 culture, 255
 clinical, 109
 epidemiology, 108–9
 HIV-AIDS patients, 213
 immunocompromised
 patients, 220
 lesions and associated
 genotypes, 109
 management, 109
 transplant recipients, 214
 types, 108
 vaccines, 171, 274, 275
- papillomaviruses (clinical),
 109
 cancers, 109
 cervical cancer, 109
 laboratory diagnosis, 109
 mucus membrane
 infections, 109
 other cancers, 109
 skin infections, 109
- papillomaviruses
 (epidemiology), 108–9
 at-risk groups, 109
 incubation period, 108
 infectious period, 109
 prevalence, 108
 route of spread, 108
- papillomaviruses
 (management), 109
 infection control, 109
 prophylaxis, 109
 treatment (cervical cancer),
 109
 treatment (warts), 109
 vaccine products, 109
- Papua New Guinea, 155, 224
 parainfluenza viruses, 192
 common cold, 197, 198
 epidemiology, 101–2
 immunocompromised
 patients, 219
 respiratory viral infections,
 195
 respiratory virus symptoms
 in different groups of
 patients, 194
 parainfluenza viruses (PIV)
 clinical, 102–4
 definition, 101
 management, 105
 serotypes, 101
- parainfluenza viruses
 (clinical), 102–4
 adults, 103
 children, 103
 differential diagnosis, 104
 laboratory diagnosis, 104
- parainfluenza viruses
 (epidemiology), 101–2
 at-risk groups, 102
 incubation period, 102
 infectious period, 102
 prevalence, 101
 route of spread, 101
- parainfluenza viruses
 (management)
 infection control, 105
 treatment, 105
- parainfluenza viruses (types)
 PIV-1, 101, 103
 PIV-2, 101, 103
 PIV-3, 101, 102
 PIV-4, 101, 102
- Paramyxoviridae family
 measles virus, 88, 101
 mumps virus, 94, 101
 parainfluenza viruses, 101
- parapox viruses, 116, 119, 234
 electron micrograph, 120
- parental transmission:
 hepatitis B virus, 36
- paritaprevir, 47, 270, 271
 parotid gland, 95, 164
 parotitis, 94
 particle size, 5
- Parvoviridae, 1
 parvovirus B19, 111
 parvovirus B19, 6, 111–15
 cannot be grown in cell
 culture, 255
 clinical, 112–13
 congenital infections
 (diagnosis), 187
 definition, 111
 epidemiology, 111
 immunocompromised
 patients, 220
 maculopapular skin rashes
 (laboratory diagnosis),
 229
 management, 113–15
 postnatal infection, 186
 skin rash of erythema
 infectiosum, 230

	Index	313
transplant recipients, 214 vertical transmission, 182 viral rashes, 228 parvovirus B19 (clinical), 111 complications, 112 erythema infectiosum, 112 infections in immunocompromised, 113 infections in pregnancy, 112 laboratory diagnosis, 114 myocarditis, 113 patients with haemolytic anaemia, 113 parvovirus B19 (epidemiology), 111 at-risk groups, 111 incubation period, 111 infectious period, 111 prevalence, 111 route of spread, 111 parvovirus B19 (management), 113–15 infection control, 115 prophylaxis, 115 treatment, 113 Paul Bunnell test, 173, 173 paxlovid, 72, 267, 269 pegylated interferon alpha, 40, 41, 210, 267, 271, 289 pegylated interferon: HCV, 46 pelvic inflammatory disease (PID), 146, 148, 170 penciclovir, 265 viral life-cycle target, 264 penicillins, 157 peramivir, 86 viral life-cycle target, 264 perforins, 4 pericarditis, 29 perinatal infection, 181 personal protective equipment (PPE), 178, 292 persons who inject drugs (PWID), 30, 44, 45, 48, 60, 61, 66, 80 petechial rash, 12, 14, 20, 151, 164, 178 Pfizer mRNA vaccine, 72 pH, 2, 5 phagocytic cells, 4 phagocytosis, 5 pharyngitis, 28 <i>Phlebovirus</i> genus, 13 Rift Valley fever virus, 17 phosphorylation, 263, 264	physical barriers: examples, 4 pibfentasvir, 46, 210, 270, 271 Picornaviridae family enteroviruses, 27–9 hepatitis A virus (HAV), 30–3 rhinoviruses, 128 pigs, 50, 51, 83, 84, 149, 237 plantar warts (veruccas), 234 plaques, 156 plasma cells, 4, 5 <i>Pneumocystis carinii</i> pneumonia (PCP), 62 Pneumocystis jiroveci, 62 pneumonia, 8, 62, 69, 71, 77, 101, 103, 124, 192 pneumonitis, 28, 55, 56, 68, 91, 113, 190, 220 Pneumoviridae family human metapneumovirus, 77 respiratory syncytial virus (RSV), 124 point source outbreaks, 284 point-of-care tests (POCTs), 104, 246, 250, 252–3, 257, 260 polio, 5, 27, 29, 274 at-risk groups, 27 incubation period, 27 vaccination, 29 whole-virus inactivated vaccine, 275 polio virus, 277 poliomyelitis, 28 vaccination (healthcare workers), 287 polioviruses, 27 polyarthropathy, 158 polyethylene glycol (PEG), 267 polymerase chain reaction (PCR), 9, 26, 28, 47, 68, 72, 86, 95, 104, 164, 209, 251 cycle threshold value, 250 molecular technique, 250–1 variations, 250–1 Polyomaviridae family, 108 polyomaviruses, 109 polyomavirus 1, <i>see</i> BK virus polyomavirus 2, <i>see</i> JC virus polyomaviruses, 109–10 definition, 108 immunocompromised patients, 220	transplant recipients, 214 types, 108 porcupines, 177 Portugal, 59, 118 post-exposure prophylaxis (PEP), 66, 288, 289 HIV, 65 post-herpetic neuralgia, 139 post-infectious encephalitis: CNS viral infections, 162 postnatal infection, 184–8 <i>Chlamydia trachomatis</i> , 188–90 cytomegalovirus, 184–5 definition, 181 diagnosis of congenital infections, 187 follow-up (babies suspected of vertically acquired infection), 190 herpes simplex virus, 186–8 maternal genital herpes infection (management), 188 parvovirus B19, 186 rubella, 184 Toxoplasma, 186 varicella-zoster virus, 185–6 viral and related congenital infections, 182 post-transplant lymphoproliferative disease (PTLD), 24, 25, 213, 217, 226–7 rituximab, 266 symptoms, 227 poultry, 84, 85, 237 pox viruses, 116–20 cowpox, 117–18 definition, 116 electron micrograph, 120 genera (four), 116 infection control, 120 infections, 120 laboratory diagnosis, 119 milker's nodule, 119 molluscum contagiosum, 119 monkeypox, 118–19 orf virus, 119 smallpox, 116–17 useful websites, 120 vesicular skin rashes (laboratory diagnosis), 231 viral rashes, 234

314	Index
Poxviridae family (pox viruses), 116	pathogenesis, 153
prednisone, 109	prion protein (PrP) disease (types)
pre-exposure prophylaxis (PrEP), 66	cellular (PrP ^c), 153, 154
HIV, 65	resistant (Pr P ^{Res}), 153, 155
pregnancy, 16, 19, 37, 85, 92, 118, 134, 148	scrapie (Pr P ^{Sc}), 153, 154, 155
antivirals (acting by DNA polymerase inhibition) 'not licensed', 263	probenecid, 265
chickenpox, 139, 233	proctitis, 146
<i>Chlamydia abortus</i> infection, 158	progressive multifocal leucoencephalopathy (PML), 62, 108, 109, 162, 220
CMV, 20	prophylaxis
doxycycline and ciprofloxacin 'contraindicated' (specific context), 159	adenoviruses, 9
Ebola, 178	cytomegalovirus, 22
genital infection, 170	enteroviruses, 28–9
healthcare workers, 126	gastroenteritis viruses, 167
hepatitis E, 50, 51, 53	hepatitis A virus, 31–2
HIV, 66	herpes simplex virus, 57
miscarriage caused by <i>C. abortus</i> infection, 147	HIV, 65
parvovirus B19, 112, 113	human herpesviruses HHV 6–8, 76
rubella, 135, 228	human T-cell lymphotropic viruses, 81
rubella (fetal malformation), 135	immunocompromised patients (virus infections), 221
rubella vaccination contraindicated, 137	influenza viruses, 86
some live vaccines contraindicated, 275	measles, 91–2
<i>Toxoplasma</i> infection (congenital transmission), 150	mumps, 96
useful website, 191	papillomaviruses, 109
VZV, 139, 290	parvovirus B19, 115
pregnancy (infections)	rabies virus, 123
congenital infection, 181	respiratory syncytial virus, 126
laboratory diagnosis and management, 191	rhinoviruses, 129
maculopapular viral rash, 190	rotaviruses (management), 132
perinatal infection, 181	rubella virus, 136
vesicular rash, 189	sexually transmitted infections, 171
viral rash, 189	<i>Toxoplasma gondii</i> infections, 152
primary influenza pneumonia, 85	varicella-zoster virus, 141–2
primary measles encephalitis, 90	viral hepatitis, 210
primary monkey kidney (PMK) cell line, 255	prostatitis, 146, 169
primates, 13, 177, 238, 240	protease inhibitors (PIs), 271, 272
prion protein (PrP) disease, 239	proto-oncogenes, 222
clinical, 155	protozoan parasites:
	<i>Toxoplasma gondii</i> , 149
	pro-viral DNA, 79, 223
	psittacine birds, 158
	psittacosis, 158
	treatment, 158
	public education, 283
	public health, 292–5
	laboratory services for next pandemic, 293–5
	pandemic preparedness, 292–3
	responding to new pandemic, 293
	Public Health England (PHE), 294
	Public Health Laboratory Service (PHLS, UK), 293
	purpuric rash, 135, 184
	<i>Puumala</i> virus, 179
	pyrexia of unknown origin (PUO), 200
	pyrimethamine, 151, 186, 206, 220
	<i>T. gondii</i> treatment, 215–16
	pyroptosis, 60
	pyrrolizidine alkaloids, 225
	Q fever, <i>see</i> <i>Coxiella burnetii</i>
	quality control (laboratories), 258–60
	audit (clinical), 259
	audit (horizontal), 258
	audit (vertical), 258
	audit (witnessing), 258
	quality assurance, 258–9
	service provision, 258
	sources of errors, 259–60
	technical competence, 260
	quantitative PCR, 109
	Quebec, 16
	quinolones, 160
	rabies, 5
	travel-related, 200
	vaccination, 237
	rabies virus, 162, 277
	clinical, 122
	definition, 121
	epidemiology, 121–2
	management, 123
	negri body in infected neuron, 122
	useful websites, 123
	zoonotic infection spread by direct contact, 238
	rabies virus (clinical), 122
	laboratory diagnosis, 122
	symptoms, 122
	rabies virus (epidemiology), 121–2
	at-risk groups, 121

	Index	315
incubation period, 121		
infectious period, 121		
prevalence, 121		
route of spread, 121		
rabies virus (management), 123		
infection control, 123		
prophylaxis, 123		
treatment, 123		
raltegravir, 273		
rapid antigen detection test, 86		
recombinant DNA		
technology, 41, 126		
recombinant vaccines, 275, 276		
red eye, <i>see</i> conjunctivitis		
remdesivir, 267		
renal transplant recipients, 109, 220		
Reoviridae, 1		
resource-poor countries, 90, 108, 131		
respiratory adenoviruses, 8		
respiratory infections: travel-related ~, 200		
respiratory precautions, 283		
respiratory route, 5, 77, 92, 101, 111, 116, 282		
respiratory symptoms, 9		
respiratory syncytial virus (RSV), 192, 267, 269		
Cepheid test, 253		
clinical, 125–6		
common cold, 197		
definition, 124		
epidemiology, 124–5		
immunocompromised patients, 219		
immunofluorescence tests, 244		
management, 126–7		
respiratory viral infections, 195		
symptoms (different groups of patients), 194		
useful websites, 127		
respiratory syncytial virus (clinical), 125–6		
differential diagnosis, 125		
infection (laboratory diagnosis), 126		
laboratory diagnosis, 125		
symptoms, 125		
respiratory syncytial virus (epidemiology), 124–5		
at-risk groups, 125		
incubation period, 124		
infectious period, 125		
prevalence, 124		
route of spread, 124		
respiratory syncytial virus (management), 126–7		
infection control, 127		
prophylaxis, 126		
treatment, 126		
respiratory viral infections, 192–6		
infection control, 196		
influenza, 192–5		
laboratory diagnosis, 196		
other respiratory viruses, 196		
parainfluenza viruses, 195		
respiratory syncytial virus, 195		
SARS CoV-2, 195		
symptoms in different groups of patients, 193		
respiratory viruses, 254, 257		
amantadine, 266		
antiviral drugs, 266–7		
baloxavir marboxil, 267		
immunocompromised patients, 219		
molnupiravir, 267		
oseltamivir, 266		
palivizumab, 267		
paxlovid, 267		
peramivir, 266		
remdesivir, 267		
ribavirin, 266		
transplant recipients, 214		
zanamivir, 266		
<i>Respirovirus</i> genus: PIV-1 and PIV-3, 101		
reticulate bodies (RB): definition, 145		
reticulocytes, 113, 220		
retinal chorioretinitis, 151		
retinitis, 19, 20, 182, 204		
CMV patients, 216, 217		
retinochoroiditis, 186		
Retroviridae family		
HIV, 59		
human T-cell lymphotropic viruses, 79		
retroviruses: first to be isolated (1979), 79		
reverse transcriptase (RT) enzymes, 59, 79, 223, 250, 251		
reverse transcriptase (RT) inhibitor, 267		
reverse transcription loop-mediated isothermal amplification (RT-LAMP), 251		
reverse transcription PCR (RT-PCR), 250		
Rhabdoviridae family: rabies virus, 121		
rhinoviruses, 27, 28, 68, 192, 196		
clinical, 128–9		
common cold, 197		
definition, 128		
epidemiology, 128		
management, 129		
respiratory virus symptoms in different groups of patients, 194		
rhinoviruses (clinical), 129		
differential diagnosis, 129		
infections, 129		
laboratory diagnosis, 129		
symptoms, 129		
rhinoviruses (epidemiology), 128		
at-risk groups, 128		
incubation period, 128		
infectious period, 128		
prevalence, 128		
route of spread, 128		
rhinoviruses (management), 129		
infection control, 129		
prophylaxis, 129		
treatment, 129		
ribavirin, 9, 126, 195, 210, 269, 271, 289		
definition, 266		
HCV, 46		
hepatitis E treatment, 214, 219		
immunocompromised patients, 195		
intravenous, 126		
Lassa fever, 175, 177, 234		
organ transplant recipients, 52		
PIV cases, 105		
RNA viruses, 266		
viral life-cycle target, 264		
Rift Valley fever virus (RVFV), 13, 17, 239, 240		
diagnosis, 17		
ritonavir, 72, 195, 272		
rituximab, 269		
PTLD, 26, 217		

316	Index
rituximab (cont.) viral life-cycle target, 264 RNA genomes, 1, 3 RNA polymerase, 3, 46, 251, 267, 271 RNA viruses detection, 250 hepatitis E, 50 HIV, 59 human metapneumovirus, 77 influenza viruses, 83 measles virus, 88 tend to be enveloped and have outer proteins, 2 usually single-stranded, 1 roseola infantum, 75 rotavirus A, 130, 132 rotaviruses, 8, 98, 130–3, 277 cannot be grown in cell culture, 255 clinical, 131 definition, 130 differential diagnosis (electronic microscopy), 255 electron micrograph, 131 epidemiology, 130–1 management, 132–3 species (nine), 130 useful website, 133 rotaviruses (clinical), 131 differential diagnosis, 131 infections, 132 laboratory diagnosis, 131 symptoms, 131 rotaviruses (epidemiology), 130–1 at-risk groups, 131 incubation period, 130 infectious period, 131 prevalence, 130 route of spread, 130 rotaviruses (management), 132–3 infection control, 132 prophylaxis, 132 treatment, 132 rubella, 248 congenital, 135 congenital infections (diagnosis), 187 postnatal, 135, 184 vaccination (healthcare workers), 287 viral rashes, 228	rubella virus, 5, 134–7, 162, 277 clinical, 135 definition, 134 epidemiology, 134 maculopapular skin rashes (laboratory diagnosis), 229 management, 135–7 possesses haemagglutinin antigen, 246 vaccination, 134, 275 vertical transmission, 182 rubella virus (clinical), 135 complications, 135 congenital rubella, 135 laboratory diagnosis, 136 postnatal rubella, 135 rubella virus (epidemiology), 134 at-risk groups, 134 incubation period, 134 infectious period, 134 prevalence, 134 route of spread, 134 rubella virus (management), 135–7 infection control, 137 prophylaxis (post-exposure), 136 prophylaxis (pre-exposure), 136 treatment, 135 <i>Rubivirus</i> genus: rubella virus, 134 <i>Rubulavirus</i> genus: PIV-2 and PIV-4, 101 Russian Federation, 50, 72, 116 Sabin vaccine: contraindicated in immunosuppressed people, 29 <i>Saccharomyces cerevisiae</i>, 275 safe sex, 66, 82 salad, 30, 97, 200 saliva, 24, 121, 122, 243 salivary samples, 248 Salk polio vaccine, 29 salpingitis, 146, 170 Sanger sequencing, 252 Sanofi recombinant viral spike protein vaccine, 72 sapoviruses, 98, 165 saquinavir, 272 SARS coronavirus (SARS CoV), 67, 237 diagnostic tests, 69 fatality rate, 68 incubation period, 68 nursing, 68 route of spread, 67 smaller outbreak (2004), 68 symptoms, 68 worldwide outbreak (2003), 68 zoonotic infection spread by direct contact, 238 SARS CoV-2, 1, 69–73, 246, 267, 269, 276, 284, <i>see also</i> Covid-19 aetiological agent of Covid-19 pandemic, 67 antigen tests, 72 Cepheid test, 253 clinical presentation, 70–1 electron microscopic image, 68 epidemiology, 69–70 immunocompromised patients, 219 infection and outbreak control (healthcare setting), 290 point-of-care tests, 253 respiratory viral infections, 195 respiratory virus symptoms in different groups of patients, 193 serology, 72 test results, 257 transcription-mediated amplification, 251 variants, 70 zoonotic infection, 237 zoonotic infection spread by direct contact, 239 SARS CoV-2 (clinical), 70–1 adults, 70 at-risk groups, 71 children, 71 fatality rate, 71 symptoms (adults), 71 symptoms (children), 71 SARS CoV-2 (epidemiology), 69–70 incubation period, 70 infectivity period, 70 route of spread, 70 Saudi Arabia, 17, 69

	Index	317
Scandinavia, 179		
schools, 98, 119, 157		
scleritis, 204		
scrapie, 156		
clinical, 154		
epidemiology, 153		
prevalence, 154		
route of spread (animals), 154		
scrapie fibrils, 153, 156		
screening programmes, 283		
seasonal human coronaviruses (seasonal HCoV)		
incubation period, 67		
symptoms, 67		
Sedoreoviridae family:		
rotaviruses, 130		
semen, 24, 74, 178		
Senegal, 239		
seroconversion, 21, 41, 46, 61, 64, 81, 141, 160, 200, 289		
serological techniques, 243–9		
acute infection (diagnosis), 244		
conclusion, 249		
diagnostic uses, 247		
past infection (diagnosis), 244		
principle, 243		
types, 244–8		
use of non-serum samples for antibody tests, 248		
serological techniques (types), 244–8		
antibody avidity assays, 248		
complement fixation test, 246		
enzyme-linked immunosorbent assays (ELISA), 244–5		
gelatin particle agglutination test, 246		
haemagglutination inhibition tests, 246		
immunofluorescence tests, 246		
lateral flow tests, 246		
latex agglutination, 246		
line immunoassays, 248		
neutralisation tests, 248		
Western blot, 248		
serology, 81, 209		
automation, 248–9		
automation (random access), 248		
future, 249		
rapid diagnostic techniques, 249		
response to viral infection (figurative representation), 244		
serostatus, 216, 217, 221		
serotypes, 7, 14, 27, 29, 44, 101, 128, 129, 132		
severe acute respiratory syndrome (SARS), 1, 68, <i>see also</i> SARS coronavirus (SARS CoV)		
severe combined immunodeficiency disease (SCID), 125, 127, 128, 132, 194, 212		
sex, 150		
sexual activity, 119, 168		
sexual contact, 18, 22, 23, 54		
sexual health clinics, 109		
sexual intercourse, 36, 60, 66, 109, 146, 148, 200, 200, 224		
sexual partners, 36, 42, 45, 61, 80, 225		
sexually transmitted infections, 60, 81, 108, 118, 145, 168–71, 175, 177, 178, 202		
cervicitis and vaginal discharge, 169		
clinical, 168–70		
control of infection, 171		
Fitz–Hugh–Curtis syndrome, 170		
genital infection in pregnancy, 170		
genital lesions (non-vesicular or non-ulcerative), 168		
genital lesions (vesicular or ulcerative), 168		
genital warts, 109		
hepatitis B virus, 34, 36		
laboratory diagnosis, 170		
LGV, 169		
management, 171		
manifestations (local and systemic), 169		
papillomaviruses, 109		
pelvic inflammatory disease (PID), 170		
prophylaxis, 171		
prostatitis and epididymo-orchitis, 169		
systemic, 168, 169		
two groups, 168		
urethritis and urethral discharge, 169		
virus detection, 170		
Zika virus, 16		
sheep, 119, 145, 147, 148, 149, 156, 158, 159, 178, 234, 238, 240		
Sheffield Virology Laboratory, viii		
shellfish, 30, 97, 166, 200		
shingles, 6, 62, 138, 182, 218		
antiviral drugs, 142		
laboratory diagnosis, 141		
same as ‘zoster’, 139		
vaccine, 143		
shingles vesicles, 56, 140		
shipyard eye, 8, <i>see also</i> adenovirus conjunctivitis		
shistosomiasis (bilharzia), 45		
sialic acid, 2, 83, 266		
sickle cell disease, 113		
simian immunodeficiency virus (SIV), 59		
strains, 59		
simian T-lymphotropic viruses (STLVs), 79		
simian virus 40 (SV40), 109		
<i>Sin Nombre</i> virus, 179		
single-stranded RNA enveloped viruses:		
parainfluenza viruses, 101		
single-stranded RNA viruses		
coronaviruses, 67		
enteroviruses, 27–9		
hepatitis A, 30–3		
hepatitis C, 44		
mumps virus, 94		
negative versus positive strands, 1		
rabies virus, 121		
respiratory syncytial virus, 124		
rhinoviruses, 128		
rubella virus, 134		
single-stranded, non-enveloped, positive-sense RNA viruses:		
noroviruses, 97		
sinusitis, 199		
sixth disease, 75		
skin cancer, 223, 226		
skin infections, 109, 188		
papillomaviruses, 109		
viral rashes, 228		

318	Index
skin lesions, 56, 116, 119, 120, 138, 140, 162, 186, 188, 226 chickenpox (varicella), 139 slapped cheek syndrome, 112 small DNA viruses: parvovirus B19, 111 smallpox, 234, 266, 274 pox viruses, 116–17 vaccine, 117 vesicular rashes (electron microscopy), 255 smallpox virus, 277 electron micrograph, 256 Smielewska, Anna, viii smokers, 41, 199 risk of varicella pneumonitis, 139 sneezing, 5, 128, 129, 197, 198, 282 socio-economic status, 30, 31 sofosbuvir, 46, 210, 270, 271 solid organ transplants, 19, 21, 22, 52, 102, 219 CMV infection, 212 South Africa, 44 South America, 11, 14, 16, 50, 80, 223 South-East Asia, 11, 15, 44, 50, 60, 74, 209, 239 specimens (sending to laboratory), 241–2 correct specimens, 241 notification, 242 packaging, 242 request form, 241 spectrophotometer, 244 spherocytosis, 113 spike protein, 67, 70, 72, 276 sporadic Creutzfeldt-Jakob disease (CJD), 156 clinical, 155 prevalence, 154 St Louis encephalitis virus, 240 standard operating procedures (SOPs), 258 stavudine, 272 Stevens–Johnson syndrome, 158 vesicular skin rashes (laboratory diagnosis), 231 viral rashes, 233 STIs, <i>see</i> sexually transmitted infections	Streptococcus pneumoniae, 157 subacute sclerosing panencephalitis (SSPE), 90, 91 CNS viral infections, 162 sub-Saharan Africa, 14, 16, 17, 60, 74, 177, 224, 226 subunit vaccines, 275, 276–7 sulfonamide, 157 sulphadiazine, 206 summer colds, 192, 197 surface proteins, 6, 83 sustained viral response (SVR), 47, 48, 211 Sutehall, Gordon, viii swimming pools, 7, 108, 109, 119 syphilis, 168, 169, 181 T-cells, 4, 5, 227 activation, 4 deficiency, 109 depletion (risk factor for adenovirus disease), 219 derivation, 4 dysfunction, 109 T helper cells, 2, 5 Tanzania, 177 taq polymerase (bacterial enzyme), 250 T-cell receptor (TCR), 4 tecovirimat, 118 telbivudine, 271 temperate-climate countries, 102 tenofovir, 36, 269 antiviral drug, 38 tenofovir alafenamide, 40, 210, 271 tenofovir disoproxil, 40, 210 tenofovir disoproxil fumarate (TDF), 271 tetanus, 122, 278, 287 tetracyclines, 158, 159, 160 contraindicated in children, 148 Texas, 16 thalassemia, 113 thrombocytopaenia, 113, 135, 151, 178, 184, 220 thymidine kinase (TK) enzyme, 263 mutants, 264 tick-borne encephalitis, 12, 15, 240 tick-borne encephalitis virus (TBEV), 15, 239 mortality rates, 15 subtypes (three), 15 transmission, 15 vaccine, 15 tissue cysts, 149 Togaviridae family, 11, 13, 16–17 rubella virus, 134 towels, 108, 109, 119 <i>Toxoplasma gondii</i>, vii, 25, 62, 149–52, 162, 172, 206, 248 congenital infections (diagnosis), 187 definition, 149 HIV-AIDS patients, 213 immunocompromised patients, 220 laboratory diagnosis, 173, 173 life cycle, 149 postnatal infection, 186 symptoms, 172 transplant recipients, 215 useful website, 152 uveitis and retinitis, 204 vertical transmission, 182 <i>Toxoplasma gondii</i> infections clinical, 150–1 epidemiology, 149–50 management, 151–2 <i>Toxoplasma gondii</i> infections (clinical), 150–1 differential diagnosis, 151 laboratory diagnosis, 151 symptoms, 150–1 <i>Toxoplasma gondii</i> infections (epidemiology), 149–50 at-risk groups, 150 incubation period, 150 infectious period, 150 prevalence, 149 route of spread, 149 <i>Toxoplasma gondii</i> infections (management) infection control, 152 prophylaxis, 152 treatment, 151 toxoplasmosis, 186, 191 trachoma, 145, 147 definition, 146 transcription-mediated amplification (TMA), 251

	Index	319
transformed human epithelial cell line, 255		
transmissible spongiform encephalopathies (clinical), 154–6		
animal prion disease, 154		
human prion disease, 155		
laboratory diagnosis, 155		
list (human and animal), 156		
transmissible spongiform encephalopathies (epidemiology), 153–4		
at-risk groups, 154		
incubation period, 154		
infectious period, 154		
prevalence, 154		
prion protein (PrP) disease (pathogenesis), 153		
route of spread, 154		
transmissible spongiform encephalopathies (TSEs), 153–6		
clinical, 154–6		
definition, 153		
epidemiology, 153–4		
further reading, 156		
infection control, 156		
transplant recipients, 21, 74, 75		
haemorrhagic chickenpox danger, 139		
virus infections, 213		
travel history, 174		
travel vaccines, 279		
travel-related infections, 200–2		
gastroenteritis, 200		
hepatitis, 200		
medical tourism, 200		
miscellaneous, 202		
pyrexia, 200		
rabies, 200		
respiratory infections, 200		
useful websites, 202		
viral (travel outside UK), 200		
treatment		
adenoviruses, 9		
adult T-cell leukaemia (ATL), 224		
chlamydia, 148		
common cold, 199		
Covid-19, 72		
cytomegalovirus, 20–2		
Epstein–Barr virus, 25		
gastroenteritis viruses, 167		
hepatitis A virus, 31		
hepatitis B virus, 39–41		
hepatitis C virus, 46–8		
herpes simplex virus, 57		
HIV, 64–5		
human herpesviruses (HHV 6–8), 76		
immunocompromised patients (virus infections), 221		
influenza viruses, 86		
measles, 91		
mumps, 96		
noroviruses, 99		
papillomaviruses, 109		
parainfluenza viruses, 105		
parvovirus B19, 113–15		
rabies virus (management), 123		
respiratory syncytial virus, 126		
rhinoviruses, 129		
rotaviruses, 132		
rubella virus, 135		
<i>Toxoplasma gondii</i> infections, 151		
varicella-zoster virus, 140		
viral hepatitis, 211		
treponema, 169		
trimoxazole: <i>T.gondii</i> treatment, 215–16		
tropical countries, 102, 145		
tropical spastic paraparesis (TSP), 79, 80		
tropics, 11, 138, 145, 169, 174, 176		
tumour cells, 224, 255		
Uganda, 177		
ultrasound, 139, 184		
uncooked food, 30, 200		
undercooked meat, 149, 150, 152		
undercooking, 50		
United Kingdom, 34, 44, 69, 117, 130, 136, 154, 184, 209, 225		
cervical cancer, 225		
chronic HCV infection (2020), 44		
CMV prevalence, 18		
Department of Health, 294		
EBV, 23		
HDV infection, 42		
hepatitis B (neonatal vaccination), 37		
HIV diagnoses (2020), 59		
intravenous drug use, 45		
measles, 229		
monkeypox cases, 118		
polio vaccines, 29		
pox viruses, 116		
tick-borne encephalitis (TBE), 15		
<i>Toxoplasma gondii</i> infections (prevalence), 149		
vaccines recommended for pre- and post-exposure prophylaxis, 278		
variant CJD, 155		
viral vaccines, 276		
United Kingdom		
Accreditation Service (UKAS), 260		
United Kingdom Advisory Panel (UKAP), 290		
United Kingdom Health Security Agency (UKHSA), viii, 8, 32, 192, 294, 295		
virus reference laboratory, 123		
United Kingdom Influenza Preparedness Strategy (2011), 292		
United Kingdom: Department for Transport, 242		
United States, 16, 80, 116, 117, 179, 184, 209, 225		
military personnel, 9		
upper respiratory tract infections (URTIs), 103, 125		
urethritis, 146, 169, 169		
urinary tract infection (UTI), 169		
urine, 177, 179, 243, 248		
atypical pneumonia, 160		
uveitis, 178, 182, 204		
vaccination		
etymology, 117		
varicella-zoster virus, 142		
vaccination strategy, 277–8		
vaccines recommended for pre- and post-exposure prophylaxis (UK), 278		
vaginal discharge, 169, 170		

320	Index
valaciclovir, 22, 57, 141, 185, 206, 268 definition, 265 HSV, 171, 218, 232 VZV, 218, 233 zoster treatment, 231	vaccination (healthcare workers), 287 vaccine, 274 vertical transmission, 182 vesicular skin rashes (laboratory diagnosis), 231 viral encephalitis, 161–2 viral rashes, 232
valganciclovir, 22, 76, 185, 268 ‘can cause leukopaenia’, 22 CMV, 20, 213, 215, 216 definition, 265 HSV-2 and VZV meningitis, 163 mechanism of action, 265 resistance, 265	varicella-zoster virus (clinical), 139–40 differential diagnosis, 140 infection in pregnancy, 139, 143 laboratory diagnosis, 141 symptoms, 139 typical chickenpox rash, 140
valine ester, 265 variant Creutzfeldt-Jakob disease (vCJD), 156, 237, 239 at-risk groups, 154 clinical, 155 epidemiology, 153 infection control, 156 infectious period, 154 laboratory diagnosis, 155 route of spread, 154	varicella-zoster virus (epidemiology), 138–9 at-risk groups, 138 incubation period, 138 infectious period, 138 prevalence, 138 route of spread, 138
varicella-zoster immune globulin (VZIG), 140 varicella-zoster virus (VZV), 5, 6, 55, 56, 62, 120, 138–43, 162, 163, 168, 169, 170, 204, 248, 255, 265, 268, 277 aciclovir treatment, 263 can cause meningitis or meningoencephalitis, 161 chemoprophylaxis, 221 clinical, 139–40 definition, 138 electron micrograph, 256 epidemiology, 138–9 fetal and neonatal infection, 185–6 HIV-AIDS patients, 213 immunocompromised patients, 218 infection and outbreak control (healthcare setting), 290 management, 140–3 maternal chickenpox, 185 Oka strain, 142 postnatal infection, 185–6 retinitis, 203 transplant recipients, 231 useful websites, 143	varicella-zoster virus (management), 140–3 antiviral drugs for treating chickenpox and shingles, 142 infection control, 143 prophylaxis, 141 treatment, 140 vaccination, 142
	vector-borne (route of infection), 283 velapatasvir, 46, 210, 270, 271 Venezuela, 16 Venezuelan equine virus, 240 verrucae planae (flat warts), 109 verrucae vulgaris (common warts), 109 vertical transmission (mother-to-baby), 34, 36, 60, 74, 82, 108, 149, 150, 151, 283 vesicular rashes, 228 laboratory diagnosis, treatment, prevention, 231 viral rashes, 231
	viraemia, 45, 51, 109, 111, 134, 138, 217, 219, 282 definition, 282 primary versus secondary, 6 viral assembly and release, 3
	viral cell tropism, 254, 282 viral DNA, 3, 39, 241, 251, 264, 266, 273, 275 viral DNA polymerase, 264, 264, 265 viral encephalitis, 161–2 congenital viral encephalitis, 162 differential diagnosis, 162 herpes simplex virus, 161 laboratory diagnosis, 164 other viruses, 162 viral eye infections, 203–4 conjunctivitis, 203 diagnosis and treatment, 205 herpes zoster ophthalmicus, 204 keratitis, 204 viral gastroenteritis, 165, 167 differential diagnosis (electronic microscopy), 255 viral genome, 2, 6 transcription and translation, 2–3 viral hepatitis, 207–11 clinical, 207 clinical and epidemiological features, 208 control of infection, 210 differential diagnosis, 207 epidemiology, 209 laboratory investigations, 209 laboratory markers and clinical interpretation, 209 management, 211 prophylaxis, 210 viral infection: serological response (figurative representation), 244 viral load trends, 242 viral malignancies, 222–7 cancer (how caused), 222 control, 227 viral malignancies (types), 222–7 adult T-cell lymphoma, 223–4 Burkitt’s lymphoma, 224 cervical cancer, 224–5 hepatocellular carcinoma, 225 Hodgkin’s lymphoma, 225

- Kaposi's sarcoma, 226
 Merkel cell carcinoma, 226
 nasopharyngeal carcinoma, 226
 post-transplant lymphoproliferative disease, 226–7
 viral meningitis: CNS viral infections, 163
 viral package, 3
 viral pathogenesis, 5–6
 definition, 5
 host factors, 6
 viral persistence, 6
 viral spread, 5
 viral tropism, 5
 viral virulence factors, 6
 viral proteins, 2, 3, 248, 275
 viral rashes, 236
 adenoviruses, 231
 enteroviruses, 230, 234
 haemorrhagic rashes, 234
 herpes simplex virus, 231
 human herpesviruses (types 6–7), 231
 human parvovirus B19, 228
 maculopapular rashes, 228
 measles, 229
 poxviruses, 234
 rubella, 228
 Stevens–Johnson syndrome, 233
 useful website, 236
 varicella-zoster virus, 232
 vesicular rashes, 231
 wart-like rashes, 234
 viral RNA, 3, 59, 79, 90, 179, 209, 223, 241, 251, 267
 viral spread, 5–6
 viral taxonomy, 1–2
 viral tropism, 5
 viral vaccine (types)
 adenovirus vector vaccines, 275–6
 DNA vaccines, 275
 inactivated virus vaccines, 275
 killed virus vaccines, 275
 live attenuated virus vaccines, 274–5
 mRNA vaccines, 275
 recombinant and subunit vaccines, 275
 viral vaccines, 274–8
 United Kingdom, 276
 useful website, 278
 vaccination strategy, 277–8
 viral virulence factors:
 definition, 6
 viral zoonotic infection, 237–40
 virion envelope glycoproteins (gp120), 60
 virology, 1–6
 conclusion, 6
 history of viruses, 1
 immune response (adaptive), 4–5
 immune response (innate), 4
 immune response to viruses, 3–4
 viral pathogenesis, 5–6
 viral taxonomy, 1–2
 virus replication, 2–3
 virology laboratory services:
 preparation for next pandemic, 293–5
 viruria, 109
 virus capsid antigen (VCA), 26
 virus cell culture: virus detection (non-molecular technique), 254–5
 virus detection (non-molecular techniques)
 antigen detection, 256
 electron microscopy, 255–6
 point-of-care tests, 257
 virus cell culture, 254–5
 virus genome sequencing, 252
 virus infections
 immunocompromised patients, 212–21
 vesicular skin rashes (laboratory diagnosis), 231
 virus particles, 2, 3, 97, 130, 133, 254, 266, 272
 virus replication, 2–3
 attachment, 2
 cell entry, 2
 transcription and translation of viral genome, 2–3
 viral assembly and release, 3
 virus disassembly or uncoating, 2
 viruses
 antibodies (not present until about 10 days), 241
 etymology, 1
 history, 1
 shape (helical or icosahedral), 2
 viruses (route of entry and spread), 282–3
 blood-borne, 282
 gastrointestinal or faecal-oral route, 282
 genital tract, 283
 respiratory route, 282
 vector-borne, 283
 vertical route of infection, 283
 virus-like particles (VLPs), 225, 275
 vomiting, 9, 16, 165
 voxilaprevir, 47, 210, 270, 271
 wart-like lesions, 228
 wart-like rashes, 234
 warts, 108, 109
 treatment, 109
 water supplies, 50
 West Africa, 42, 44, 59, 118, 174, 175, 177, 178
 West Nile fever, 12, 14–15
 incubation period, 14
 mortality, 15
 outbreaks, 14
 symptoms, 15
 zoonotic infection spread by indirect contact via arthropod vector, 240
 Western blot (WB), 247, 248
 Western equine encephalitis (WEE), 16
 Western equine virus, 13, 240
 wild type virus, 274
 Wisconsin, 16
 World Health Organization (WHO), 15, 27, 37, 54, 121, 274, 293
 global elimination of HCV infection (2030 target), 48
 Wreghitt, Tim, 140, 257
 X chromosome, 24
 yatapoxvirus, 116
 yellow fever, 44, 239
 yellow fever virus (YFV), 208, 277
 incubation period, 14

322	Index
yellow fever virus (YFV) (cont.) mortality, 14 symptoms (acute illness), 14 transmission cycles (three types), 14 vaccine, 14 zoonotic infection spread by indirect contact via arthropod vector, 240 Yemen, 17 zalcitabine, 272 zanamivir, 86, 87, 266, 269	treatment of influenza, 195 viral life-cycle target, 264 zidovudine, 271, 272 ATL (leukaemic forms), 224 viral life-cycle target, 264 Zika virus (ZV), 12, 15–16, 237, 239, 240 Brazilian outbreak (2015), 16 complications, 16 symptoms, 16 transmission, 16 zoonoses, 177 definition, 237 zoonotic infections, 50, 121, 159, 292 spread by direct contact (examples), 238 spread by indirect contact via arthropod vector (examples), 240 zoster, 139 same as ‘shingles’, 139 subunit vaccine, 275 typical rash, 233 zoster immunoglobulin (ZIG), 185, 213, 290 zoster sine herpetate, 139